abdominal B-PHE
mass I-PHE
; O
accumulation O

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
infectious B-PHE
and O
parasitic B-PHE
disease I-PHE
( O
unspecified O
) O
and O
pediatric O
indications O
. O

-DOCSTART- O


Treatment O
of O
protracted O
diarrhea B-PHE
due O
to O
hypofunction B-PHE
of I-PHE
the I-PHE
spleen I-PHE
, O
seminal B-PHE
emission I-PHE
, O
leukorrhagia B-PHE
, O
palpitation B-PHE
, O
insomnia B-PHE
. O

-DOCSTART- O


it O
contains O
polysaccharide O
and O
polypeptide O
mainly O
. O

1 O
Inhibiting O
synthesis B-PHE
of I-PHE
DNA I-PHE
and I-PHE
RNA I-PHE
in O
cancer O
cells O
. O

2 O
Inhibiting O
sarcoma180 B-PHE
and O
Ehrlich-Ascites B-PHE
tumor I-PHE
in O
vitro O
. O

-DOCSTART- O


injury B-PHE
due O
to O
trauma B-PHE

-DOCSTART- O


Rikkunshito O
, O
an O
herbal O
medicine O
, O
suppresses O
cisplatin-induced B-PHE
anorexia I-PHE
in O
rats O
via O
5-HT2 O
receptor O
antagonism O
. O

-DOCSTART- O


Heat B-PHE
sensation I-PHE
in O
the O
chest O
, O
palms O
and O
soles O

-DOCSTART- O


To O
nourish O
blood B-PHE
and O
consolidate O
the O
yin O
; O

To O
pacify O
the O
liver B-PHE
and O
stop O
pain B-PHE
; O

To O
soothe O
liver O
yang O

-DOCSTART- O


Penbutolol O
is O
indicated O
in O
the O
treatment O
of O
mild O
to O
moderate B-PHE
arterial I-PHE
hypertension I-PHE
. O

It O
may O
be O
used O
alone O
or O
in O
combination O
with O
other O
antihypertensive O
agents O
, O
especially O
thiazide-type O
diuretics O
. O

Penbutolol O
is O
contraindicated O
in O
patients O
with O
cardiogenic B-PHE
shock I-PHE
, O
sinus B-PHE
bradycardia I-PHE
, O
second B-PHE
and I-PHE
third I-PHE
degree I-PHE
atrioventricular I-PHE
conduction I-PHE
block I-PHE
, O
bronchial B-PHE
asthma I-PHE
, O
and O
those O
with O
known O
hypersensitivity B-PHE
. O

-DOCSTART- O


To O
quicken O
blood B-PHE
and O
nourish O
heart B-PHE
, O
constrain O
lung B-PHE
and O
astringe B-PHE
intestines O
. O

-DOCSTART- O


Similar O
to O
zidovudine O
, O
efavirenz O
inhibits O
the O
activity B-PHE
of I-PHE
viral I-PHE
RNA-directed I-PHE
DNA I-PHE
polymerase I-PHE
( O
i.e O
. O
, O
reverse B-PHE
transcriptase I-PHE
) O
. O

Antiviral O
activity O
of O
efavirenz O
is O
dependent O
on O
intracellular O
conversion O
to O
the O
active O
triphosphorylated O
form O
. O

The O
rate O
of O
efavirenz O
phosphorylation O
varies O
, O
depending O
on O
cell O
type O
. O

It O
is O
believed O
that O
inhibition O
of O
reverse B-PHE
transcriptase I-PHE
interferes O
with O
the O
generation B-PHE
of I-PHE
DNA I-PHE
copies I-PHE
of I-PHE
viral I-PHE
RNA I-PHE
, O
which O
, O
in O
turn O
, O
are O
necessary O
for O
synthesis O
of O
new O
virions O
. O

Intracellular O
enzymes O
subsequently O
eliminate O
the O
HIV B-PHE
particle I-PHE
that O
previously O
had O
been O
uncoated O
, O
and O
left O
unprotected O
, O
during O
entry O
into O
the O
host O
cell O
. O

Thus O
, O
reverse O
transcriptase O
inhibitors O
are O
virustatic O
and O
do O
not O
eliminate O
HIV B-PHE
from O
the O
body O
. O

Even O
though O
human O
DNA B-PHE
polymerase I-PHE
is O
less O
susceptible O
to O
the O
pharmacologic O
effects O
of O
triphosphorylated O
efavirenz O
, O
this O
action O
may O
nevertheless O
account O
for O
some O
of O
the O
drug's O
toxicity O
. O

-DOCSTART- O


Dexamethasone O
is O
a O
glucocorticoid B-PHE
agonist I-PHE
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Physical B-PHE
performance I-PHE
and O
fitness O
, O
absorption B-PHE
, O
Strength O
and O
power O
, O
Liver B-PHE
health I-PHE
, O
Inflammation B-PHE
, O
Liver B-PHE
, O
Others O
, O
motility B-PHE

-DOCSTART- O


However O
, O
like O
other O
antihypertensives O
, O
they O
all O
have O
to O
be O
self-administered O
daily O
and O
don't O
provide O
a O
good O
solution O
for O
improving O
patient O
compliance O
. O

-DOCSTART- O


( O
1 O
) O
/ O
morbid B-PHE
leukorrhea I-PHE
; O
( O
2 O
) O
gynecological B-PHE
diseases I-PHE
( O
in O
a O
broad O
sense O
) O

-DOCSTART- O


To O
cause O
catharsis O
and O
purge O
away O
heat B-PHE
, O
to O
reduce O
heat B-PHE
in O
blood B-PHE
and O
counteract O
toxicity B-PHE
, O
and O
to O
eliminate O
blood B-PHE
stasis I-PHE
and O
stimulate O
menstrual B-PHE
discharge I-PHE
. O

-DOCSTART- O


blood B-PHE
vomiting I-PHE
due O
to O
weakness B-PHE
and O
fatigue B-PHE

-DOCSTART- O


To O
clear O
away O
heat B-PHE
and O
toxic B-PHE
materials I-PHE
, O
remove O
dampness B-PHE
and O
destroy O
trichomonad B-PHE
and O
fungus B-PHE
, O
remove O
the O
necrotic B-PHE
tissue I-PHE
and O
promote O
granulation B-PHE
, O
and O
arrest O
pain B-PHE
by O
removing O
blood B-PHE
stasis I-PHE
. O

-DOCSTART- O


To O
reduce O
masses B-PHE
by O
dissipating O
blood B-PHE
stasis I-PHE
, O
and O
to O
relieve O
pain B-PHE
by O
removing O
stagnancy B-PHE
of O
food O
. O

-DOCSTART- O


Pneumonia B-PHE
, I-PHE
Pneumocystis I-PHE
Carinii I-PHE

-DOCSTART- O


Treatment O
of O
attack O
of O
damp-heat B-PHE
manifested O
by O
stuffiness B-PHE
and O
fullness O
sensation O
in O
the O
abdomen B-PHE
, O
or O
causing O
acute B-PHE
dysentery I-PHE
of O
jaundice B-PHE
, O
high O
fever B-PHE
accompained O
by O
impairment B-PHE
of O
conciousness B-PHE
, O
fidgetness O
and O
insomnia B-PHE
due O
to O
exuberant O
fire O
, O
spitting B-PHE
of I-PHE
blood I-PHE
and O
epistaxis B-PHE
caused O
by O
heat B-PHE
in O
the O
blood O
, O
inflammation B-PHE
of O
the O
eye O
, O
acid B-PHE
regurgitation I-PHE
, O
toothache B-PHE
, O
diabetes B-PHE
, O
carbuncles B-PHE
and O
sores B-PHE
, O
external O
use O
for O
eczema B-PHE
and O
other O
skin B-PHE
diseases I-PHE
with O
exudation O
, O
purulent B-PHE
discharge I-PHE
from O
the O
ear O
. O

Rhizoma O
Coptidis O
( O
processed O
with O
wine O
) O
Inflammation B-PHE
of O
the O
eye O
, O
ulcers B-PHE
in O
the O
mouth O
. O

Rhizoma O
Coptidis O
( O
processed O
with O
ginger O
) O
Stuffiness O
and O
fullness O
sensation O
in O
the O
abdomen B-PHE
with O
nausea B-PHE
and O
vomiting B-PHE
caused O
by O
damp-heat B-PHE
in O
combination O
with O
cold B-PHE
. O

-DOCSTART- O


vigilance O
, O
Physical B-PHE
performance I-PHE
and O
fitness O
, O
Endurance O
, O
activation O
, O
attention O
, O
energy B-PHE
supply I-PHE
and O
recovery O
, O
Metabolism B-PHE
, O
sleep B-PHE
, O
Memory B-PHE
, O
Arousal B-PHE
, O
Others O
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


To O
strengthen O
spleen B-PHE
and O
benefit O
dampness B-PHE
; O

To O
kill O
worms B-PHE
and O
stop O
diarrhea B-PHE

-DOCSTART- O


five O
kinds O
of O
fluid-retention B-PHE
syndromes I-PHE

-DOCSTART- O


Wind-damp B-PHE
impediment O
pain B-PHE
, O
toothache B-PHE
, O
knee B-PHE
joint I-PHE
pain I-PHE
, O
scab B-PHE
and O
lichen B-PHE
, O
eczema B-PHE
, O
trichomoniasis B-PHE
, O
scalds B-PHE
, O
wound B-PHE
, O
enduring B-PHE
sores I-PHE
, O
bilharziosis B-PHE
, O
cough B-PHE
and O
asthma B-PHE
. O

-DOCSTART- O


settle O
fright O

-DOCSTART- O


[Case O
of O
pneumonitis B-PHE
caused O
by O
Yokukansan] O
. O

-DOCSTART- O


Reducing O
signs O
and O
symptoms O
of O
Crohn's B-PHE
disease I-PHE
and O
treatment O
of O
moderately O
to O
severely O
active O
rheumatoid B-PHE
arthritis I-PHE
( O
RA B-PHE
) O
. O

-DOCSTART- O


Treament O
of O
unprocessed O
Fructus O
Hordei O
Germinatus O
: O

Anorexia B-PHE
due O
to O
diminished B-PHE
function I-PHE
of I-PHE
the I-PHE
spleen I-PHE
, O
galactostasis B-PHE
. O

Fructus O
Hordei O
Germinatus O
( O
stir-fried O
) O
: O

Indigestion B-PHE
, O
weaning O
a O
baby O
. O

Fructus O
Hordei O
Germinatus O
( O
charred O
) O
: O

Retention B-PHE
of I-PHE
undigested I-PHE
food I-PHE
with O
epigastric B-PHE
distension I-PHE
and O
pain B-PHE
. O

-DOCSTART- O


soften O
hard B-PHE
mass I-PHE

-DOCSTART- O


strengthen O
the O
teeth B-PHE

-DOCSTART- O


Like O
other O
macrolides O
, O
it O
then O
penetrates O
bacteria O
cell O
wall O
and O
reversibly O
binds O
to O
domain O
V O
of O
the O
23S O
ribosomal O
RNA O
of O
the O
50S O
subunit O
of O
the O
bacterial O
ribosome O
, O
blocking O
translocation B-PHE
of I-PHE
aminoacyl I-PHE
transfer-RNA I-PHE
and I-PHE
polypeptide I-PHE
synthesis I-PHE
. O

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
Minimal O
Differentiation O

-DOCSTART- O


To O
promote O
blood B-PHE
circulation I-PHE
, O
remove O
blood B-PHE
stasis I-PHE
and O
improve O
microcirculation B-PHE
. O

-DOCSTART- O


To O
invigo O
rate O
the O
function B-PHE
of I-PHE
the I-PHE
spleen I-PHE
, O
to O
regulate O
the O
function B-PHE
of I-PHE
the I-PHE
stomach I-PHE
, O
and O
to O
promote O
the O
flow B-PHE
of I-PHE
milk I-PHE
. O

-DOCSTART- O


nourish O
bone B-PHE
marrow I-PHE

-DOCSTART- O


Swelling B-PHE
pain I-PHE
in O
joints O
, O
numbness B-PHE
in O
limbs O
, O
knocks B-PHE
and O
falls B-PHE
, O
cough B-PHE
and O
asthma B-PHE
, O
heat B-PHE
strangury I-PHE
, O
poisonous B-PHE
snake I-PHE
bite I-PHE
. O

-DOCSTART- O


To O
clear O
damp B-PHE
heat I-PHE
, O
resolve O
sore O
toxin B-PHE
, O
disperse O
swelling B-PHE
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


Dermatological B-PHE
systems I-PHE
health I-PHE
, O
General O
skin B-PHE
health I-PHE
, O
Others O

-DOCSTART- O


Sabarubicin O
blocking O
of O
DNA B-PHE
replication I-PHE
reduced O
the O
counteractive B-PHE
activity I-PHE
of I-PHE
mutagenic I-PHE
translesional I-PHE
bypass I-PHE
replication I-PHE
across O
cisplatin-DNA O
adducts O
. O

-DOCSTART- O


dryness B-PHE
of O
mouth O

-DOCSTART- O


Endurance O
, O
energy B-PHE
supply I-PHE
and O
recovery B-PHE
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE

-DOCSTART- O


Treatment O
of O
aching B-PHE
and O
weakness B-PHE
of O
the O
loins O
and O
knees O
, O
asthma B-PHE
and O
cough B-PHE
of O
deficiency-cold B-PHE
type O
, O
seminal O
emission O
, O
impotence B-PHE
. O

-DOCSTART- O


It O
causes O
blood B-PHE
vessels I-PHE
to I-PHE
narrow I-PHE
, O
resulting O
in O
an O
increase O
in O
blood B-PHE
pressure I-PHE
. O

-DOCSTART- O


To O
kill O
worms B-PHE
. O

-DOCSTART- O


sores B-PHE
due O
to O
swelling B-PHE
of I-PHE
carbuncle I-PHE
. O

-DOCSTART- O


Palonosetron O
is O
a O
selective O
serotonin O
5-HT O
3 O
receptor O
antagonist O
. O

The O
antiemetic O
activity O
of O
the O
drug O
is O
brought O
about O
through O
the O
inhibition O
of O
5-HT O
3 O
receptors O
present O
both O
centrally O
( O
medullary O
chemoreceptor O
zone O
) O
and O
peripherally O
( O
GI O
tract O
) O
. O

This O
inhibition O
of O
5-HT O
3 O
receptors O
in O
turn O
inhibits O
the O
visceral B-PHE
afferent I-PHE
stimulation I-PHE
of O
the O
vomiting O
center O
, O
likely O
indirectly O
at O
the O
level O
of O
the O
area B-PHE
postrema I-PHE
, O
as O
well O
as O
through O
direct O
inhibition O
of O
serotonin B-PHE
activity I-PHE
within O
the O
area B-PHE
postrema I-PHE
and O
the O
chemoreceptor B-PHE
trigger I-PHE
zone I-PHE
. O

Alternative O
mechanisms O
appear O
to O
be O
primarily O
responsible O
for O
delayed O
nausea B-PHE
and O
vomiting B-PHE
induced O
by O
emetogenic O
chemotherapy O
, O
since O
similar O
temporal O
relationships O
between O
between O
serotonin B-PHE
and O
emesis B-PHE
beyond O
the O
first O
day O
after O
a O
dose O
have O
not O
been O
established O
, O
and O
5-HT O
3 O
receptor O
antagonists O
generally O
have O
not O
appeared O
to O
be O
effective O
alone O
in O
preventing O
or O
ameliorating O
delayed O
effects O
. O

It O
has O
been O
hypothesized O
that O
palonosetron's O
potency O
and O
long O
plasma O
half-life O
may O
contribute O
to O
its O
observed O
efficacy O
in O
preventing O
delayed O
nausea B-PHE
and O
vomiting B-PHE
caused O
by O
moderately O
emetogenic O
cancer O
chemotherapy O
. O

-DOCSTART- O


HIV-1 B-PHE
Infections I-PHE

-DOCSTART- O


dyspepsia B-PHE
; O
indigestion B-PHE

-DOCSTART- O


blood B-PHE
vomiting I-PHE

-DOCSTART- O


refers O
to O
the O
pain B-PHE
and O
damage B-PHE
due O
to O
the O
physical O
injury B-PHE

-DOCSTART- O


Applicable O
to O
cases O
of O
watery B-PHE
diarrhea I-PHE
with O
increased O
gurgling O
sounds O
, O
abdominal B-PHE
pain I-PHE
, O
nausea B-PHE
, O
vomiting B-PHE
, O
vexation B-PHE
, O
thirst B-PHE
, O
yellow B-PHE
and I-PHE
greasy I-PHE
fur I-PHE
, O
soft O
and O
floating O
, O
smooth B-PHE
pulse I-PHE
, O
which O
are O
attributive O
to O
dampness-heat B-PHE
of I-PHE
intestines I-PHE
and I-PHE
stomach I-PHE
( O
predominantly O
da O

-DOCSTART- O


Emtricitabine O
is O
an O
analogue O
of O
cytidine O
. O

The O
drug O
works O
by O
inhibiting O
reverse B-PHE
transcriptase I-PHE
, O
the O
enzyme O
that O
copies O
HIV B-PHE
RNA I-PHE
into O
new O
viral O
DNA O
. O

By O
interfering O
with O
this O
process O
, O
which O
is O
central O
to O
the O
replication O
of O
HIV B-PHE
, O
emtricitabine O
can O
help O
to O
lower O
the O
amount O
of O
HIV B-PHE
, O
or O
viral B-PHE
load I-PHE
. O

Efavirenz O
falls O
in O
the O
NNRTI O
class O
of O
antiretrovirals O
. O

Both O
nucleoside O
and O
non-nucleoside O
RTIs O
inhibit O
the O
same O
target O
, O
the O
reverse B-PHE
transcriptase I-PHE
enzyme I-PHE
, O
an O
essential O
viral B-PHE
enzyme I-PHE
which O
transcribes O
viral O
RNA O
into O
DNA O
. O

-DOCSTART- O


To O
revitalize O
blood B-PHE
and O
desolve O
stagnation B-PHE

-DOCSTART- O


Festering O
sore B-PHE
or O
abscess B-PHE
with O
inadequate O
drainage O
or O
initial O
granulation O
. O

-DOCSTART- O


This O
is O
a O
symptom O
with O
powerlessness B-PHE
in O
a O
waist O
and O
knee O
. O

-DOCSTART- O


This O
is O
pectoral B-PHE
pain I-PHE
with O
stuffiness B-PHE
and O
pain B-PHE
in O
the O
heart O
. O

-DOCSTART- O


Glaucoma B-PHE
, O
Open-angle O

-DOCSTART- O


Chronic B-PHE
Hepatitis I-PHE
B I-PHE

-DOCSTART- O


Urinary B-PHE
Bladder I-PHE
Diseases I-PHE

-DOCSTART- O


Once O
bound O
, O
the O
receptor O
/ O
ligand O
complex O
localizes O
to O
the O
nucleus O
and O
acts O
as O
a O
DNA B-PHE
binding I-PHE
transcription I-PHE
factor I-PHE
, O
regulating O
gene B-PHE
expression I-PHE
. O

-DOCSTART- O


unblock O
the O
network B-PHE
vessels I-PHE

-DOCSTART- O


a O
diseade O
of O
chronic B-PHE
dysentery I-PHE
. O

Caused O
by O
the O
central O
Gi O
falling O
down O
due O
to O
deficiency B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
stomach I-PHE
from O
chronic B-PHE
dysentery I-PHE
. O

A O
symptom O
of O
feces B-PHE
with I-PHE
pus I-PHE
and I-PHE
blood I-PHE
and O
slight O
stomach B-PHE
pain I-PHE

-DOCSTART- O


redness B-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
a O
cold B-PHE
, O
weak B-PHE
waist I-PHE
and I-PHE
knee I-PHE
. O

-DOCSTART- O


Circulating O
Tumor B-PHE
Cells I-PHE
in O
Pancreatic O
Cancer O
Surgery O

-DOCSTART- O


Exerting O
prolong O
hypotensive B-PHE
effect I-PHE
in O
anesthetized O
animals. O
. O

-DOCSTART- O


1 O
Eliminating O
heat B-PHE
and O
toxic B-PHE
materials I-PHE
( O
carbuncle B-PHE
, O
erysipelas B-PHE
, O
burn B-PHE
, O
ulcer B-PHE
, O
sorethroat B-PHE
) O
, O
used O
as O
decoction O
, O
oral O
or O
external O
use O
, O
or O
gargle O
, O
also O
for O
the O
prevention O
and O
treatment O
of O
epidemic B-PHE
febrile I-PHE
diseases I-PHE
, O
such O
as O
influenza B-PHE
, O
epidemic B-PHE
meningitis I-PHE
, O
encephalitis B-PHE
, O
etc O
. O

2 O
. O
Clearing O
dampness-heat B-PHE
( O
diarrhea B-PHE
, O
dysentery B-PHE
and O
leukorrhagia B-PHE
of O
dampness-heat B-PHE
type O
) O
. O

Recently O
being O
used O
for O
acute O
and O
chronic B-PHE
pyelitis I-PHE
. O

3 O
To O
kill O
parasite B-PHE
( O
ancylostomoasos B-PHE
and O
filariasis B-PHE
) O
. O

-DOCSTART- O


To O
eliminate O
mass B-PHE
, O
reduce O
fullness B-PHE
, O
strengthen O
spleen B-PHE
and O
regulate O
stomach B-PHE
. O

-DOCSTART- O


Labetuzumab O
is O
a O
humanized O
monoclonal O
antibody O
used O
to O
treat O
cancer B-PHE
. O

Retrieved O
from O
http://en.wikipedia.org/wiki/Labetuzumab O

-DOCSTART- O


Tourette B-PHE
Syndrome I-PHE

-DOCSTART- O


prolonged O
chronic B-PHE
headache I-PHE

dead B-PHE
coldness I-PHE
of O
the O
extremities O

morbid B-PHE
condition I-PHE
of O
intense B-PHE
pain I-PHE
in O
the O
chest O
and O
abdomen O
, O
sudden O
coldness B-PHE
of O
the O
two O
feet O
, O
restlessness B-PHE
with O
disinclination B-PHE
ti O
eat O
and O
unsmooth O
pulse B-PHE

-DOCSTART- O


developmemt O
of O
manic B-PHE
syndrome I-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
relieve O
pain B-PHE
, O
quicken O
blood B-PHE
and O
disperse O
swelling B-PHE
. O

-DOCSTART- O


constrain O
sweat B-PHE
and O
the O
intestine B-PHE

-DOCSTART- O


( O
1 O
) O
pea-like O
skin B-PHE
sores I-PHE
; O
pox B-PHE
pea-shaped O
eruption B-PHE
filled O
with O
setrotic O
fluid O
such O
as O
smallpox B-PHE
and O
chickenpox B-PHE
. O

( O
2 O
) O
blister B-PHE

-DOCSTART- O


Cyclophosphamide's O
active O
metabolites O
aldophosphamide O
and O
phosphoramide O
mustard O
bind O
to O
DNA B-PHE
, O
thereby O
inhibiting O
DNA B-PHE
replication I-PHE
and O
initiating O
cell B-PHE
death I-PHE
. O

-DOCSTART- O


distribution O
) O
, O
Endurance B-PHE
, O
energy O
supply O
and O
recovery B-PHE
, O
Strength B-PHE
and O
power B-PHE
, O
Body B-PHE
weight I-PHE

-DOCSTART- O


a O
disease O
with O
pain B-PHE
in I-PHE
the I-PHE
joints I-PHE

-DOCSTART- O


BACKGROUND O
: O
Crohn's B-PHE
disease I-PHE
( O
CD B-PHE
) O
is O
a O
chronic B-PHE
inflammatory I-PHE
disease I-PHE
with O
increasing O
incidence O
in O
children O
. O

Current O
medications O
have O
potentially O
serious O
side O
effects O
, O
hence O
increasing O
interest O
in O
alternative O
therapies O
. O

We O
previously O
developed O
an O
herbal O
formula O
, O
FAHF-2 O
, O
based O
on O
a O
classical O
traditional O
Chinese O
herbal O
formula O
Wu O
Mei O
Wan O
that O
has O
long O
been O
used O
in O
China O
to O
treat O
colitis B-PHE
. O

We O
investigated O
FAHF-2's O
potential O
anti-inflammatory B-PHE
effects O
. O

METHODS O
: O
FAHF-2 O
efficacy O
was O
tested O
in O
vivo O
in O
the O
CD45RbRAG1 O
transfer O
colitis O
model O
. O

Weight B-PHE
loss I-PHE
, O
colonic O
histology O
, O
and O
cytokine B-PHE
production I-PHE
from O
mesenteric B-PHE
lymph I-PHE
nodes I-PHE
were O
assessed O
. O

Human O
peripheral B-PHE
blood I-PHE
mononuclear I-PHE
cells I-PHE
( O
PBMCs B-PHE
) O
and O
colonic O
biopsies O
were O
obtained O
from O
children O
newly O
diagnosed O
with O
CD O
and O
controls O
and O
cultured O
with O
or O
without O
FAHF-2 O
. O

Cytokine B-PHE
levels I-PHE
were O
measured O
by O
multiplex O
immunoassay O
. O

The O
effect O
of O
FAHF-2 O
on O
TNF-慣 B-PHE
- O
producing O
cells B-PHE
was O
determined O
by O
flow O
cytometry O
. O

NF-kB B-PHE
signaling I-PHE
was O
investigated O
in O
human O
lamina B-PHE
propria I-PHE
mononuclear I-PHE
cells I-PHE
upon O
FAHF-2 O
treatment O
by O
In O
- O
Cell O
Western O
. O

RESULTS O
: O
FAHF-2 O
- O
treated O
mice O
had O
decreased B-PHE
weight I-PHE
loss I-PHE
, O
improved O
histology O
, O
and O
reduced O
TNF-慣 B-PHE
, O
IL-17 B-PHE
, O
IL-6 B-PHE
, O
and O
IFN-y B-PHE
production O
. O

In O
vitro O
treated O
PBMCs B-PHE
produced O
less O
TNF-慣 B-PHE
, O
IFN-y B-PHE
, O
and O
IL-12 B-PHE
. O

FAHF-2 O
reduced O
the O
TNF-a B-PHE
- O
producing O
monocytes B-PHE
and O
T B-PHE
cells I-PHE
. O

-DOCSTART- O


relieve O
toxicity B-PHE
and O
alleviate O
edema B-PHE

-DOCSTART- O


Recurrent O
Childhood B-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


relieve O
heat B-PHE
and O
dissipate O
stasis B-PHE

-DOCSTART- O


Nonalcoholic B-PHE
Steatohepatitis I-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
Without O
Maturation O

-DOCSTART- O


1 O
Applicable O
to O
cases O
of O
hypovolumic B-PHE
and I-PHE
cardiogenic I-PHE
shock I-PHE
which O
are O
attributed O
to O
exhaustion B-PHE
of O
primordial O
energy O
and O
yang-energy O
. O

2 O
Also O
applicable O
to O
cases O
of O
hemorrhagic B-PHE
shock I-PHE
attributed O
to O
yang O
depletion O
. O

-DOCSTART- O


Simvastatin O
competitively O
inhibits O
HMG-CoA B-PHE
reductase I-PHE
, O
lowers O
plasma O
cholesterol O
and O
lipoprotein B-PHE
levels O
, O
and O
modulates O
immune B-PHE
responses I-PHE
by O
suppressing O
MHC O
II O
on O
interferon O
gamma-stimulated O
, O
antigen-presenting O
cells O
such O
as O
human O
vascular O
endothelial O
cells O
. O

Ezetimibe O
localizes O
and O
appears O
to O
act O
at O
the O
brush O
border O
of O
the O
small O
intestine O
and O
inhibits O
the O
absorption O
of O
cholesterol O
. O

Atorvastatin O
competitively O
inhibits O
hepatic B-PHE
hydroxymethyl-glutaryl I-PHE
coenzyme I-PHE
A I-PHE
( O
HMG-CoA B-PHE
) O
reductase O
, O
the O
enzyme O
which O
catalyzes O
the O
conversion O
of O
HMG-CoA O
to O
mevalonate O
, O
a O
key O
step O
in O
cholesterol B-PHE
synthesis I-PHE
. O

-DOCSTART- O


To O
dispel O
cold B-PHE
, O
eliminate O
damp B-PHE
and O
phlegm B-PHE
, O
and O
arrest O
emesis B-PHE
or O
nausea B-PHE
. O

-DOCSTART- O


Stagnation O
of O
qi O
in O
the O
liver O
and O
the O
stomach O
marked O
by O
distending O
pain I-PHE
in O
the O
epigastrium O
, O
feeling O
of O
stuffiness B-PHE
and O
fullness B-PHE
in O
the O
chest O
, O
anorexia B-PHE
, O
belching B-PHE
and O
acid B-PHE
regurgitation I-PHE
. O

-DOCSTART- O


dysentery B-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myelomonocytic I-PHE
Leukemia I-PHE

-DOCSTART- O


Kampo O
medicines O
are O
currently O
manufactured O
under O
strict O
quality O
controls O
. O

The O
Ministry O
of O
Health O
, O
Labour O
and O
Welfare O
of O
Japan O
has O
approved O
148 O
Kampo O
formulas O
. O

There O
is O
increasing O
evidence O
for O
the O
efficacy O
of O
Kampo O
medicines O
, O
and O
some O
are O
used O
clinically O
for O
palliative O
care O
in O
Japan O
. O

The O
specific O
aim O
of O
this O
review O
is O
to O
evaluate O
the O
clinical O
use O
of O
Kampo O
medicines O
in O
palliative O
care O
in O
the O
treatment O
of O
cancer O
. O

The O
conclusions O
are O
as O
follows O
: O
Juzentaihoto O
inhibits O
the O
progression O
of O
liver B-PHE
tumors I-PHE
in O
a O
dose-dependent O
manner O
and O
contributes O
to O
long-term O
survival O
. O

Hochuekkito O
has O
clinical O
effects O
on O
cachexia B-PHE
for O
genitourinary B-PHE
cancer I-PHE
and O
improves O
the O
QOL O
and O
immunological B-PHE
status I-PHE
of O
weak O
patients O
, O
such O
as O
postoperative O
patients O
. O

Daikenchuto O
increases O
intestinal B-PHE
motility I-PHE
and O
decreases O
the O
postoperative B-PHE
symptoms I-PHE
of O
patients O
with O
total O
gastrectomy O
with O
jejunal O
pouch O
interposition O
, O
suppresses O
postoperative O
inflammation B-PHE
following O
surgery O
for O
colorectal B-PHE
cancer I-PHE
, O
and O
controls O
radiation-induced O
enteritis B-PHE
. O

Rikkunshito O
contributes O
to O
the O
amelioration O
of O
anorectic B-PHE
conditions I-PHE
in O
cancer B-PHE
cachexia-anorexia I-PHE
syndrome I-PHE
. O

Goshajinkigan O
and O
Shakuyakukanzoto O
reduce O
the O
neurotoxicity B-PHE
of O
patients O
with O
colorectal B-PHE
cancer I-PHE
who O
undergo O
oxaliplatin O
and O
FOLFOX O
( O
5-fluorouracil/folinic O
acid O
plus O
oxaliplatin O
) O
therapy O
. O

Hangeshashinto O
has O
the O
effect O
of O
preventing O
and O
alleviating O
diarrhea B-PHE
induced O
by O
CPT-11(irinotecan O
) O
and O
combination O
therapy O
with O
S-1/CPT-11 O
. O

O'rengedokuto O
significantly O
improves O
mucositis B-PHE
caused O
by O
anticancer B-PHE
agents O
. O

-DOCSTART- O


infertility B-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
vomiting B-PHE
because O
of O
Cold-Damp B-PHE
. O

-DOCSTART- O


Symptoms O
of O
menopause B-PHE
. O

-DOCSTART- O


Excessive O
Repair O

-DOCSTART- O


dizziness B-PHE
; O
vertigo B-PHE

-DOCSTART- O


To O
replenish O
yin O
of O
the O
lung B-PHE
and O
stomach B-PHE
, O
remove O
heat B-PHE
from O
the O
lung O
, O
and O
promote O
fluid B-PHE
secretion I-PHE
. O

-DOCSTART- O


Its O
chief O
component O
is O
berberine O
. O

-DOCSTART- O


Not O
discarded O
retention B-PHE
of I-PHE
undigested I-PHE
food I-PHE

-DOCSTART- O


hemoptysis B-PHE

-DOCSTART- O


Temporomandibular B-PHE
Joint I-PHE
Dysfunction I-PHE

-DOCSTART- O


dribbling B-PHE
urination I-PHE
; O
dribbling B-PHE
of I-PHE
urine I-PHE

-DOCSTART- O


Diagnostic O
yield O
and O
adverse O
effects O
of O
MRI-guided O
free-hand O
brain O
biopsies O
through O
a O
mini-burr O
hole O
in O
dogs O
with O
encephalitis O
. O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
adverse O
effects O
( O
chemotherapy O
) O
and O
bone B-PHE
marrow I-PHE
transplant O
. O

-DOCSTART- O


Treatment O
of O
: O
1 O
Deficient O
yin O
of O
the O
lungs B-PHE
with O
heat B-PHE
manifested O
as O
dry B-PHE
cough I-PHE
or O
cough B-PHE
with O
scanty O
sputum B-PHE
, O
hoarse B-PHE
voice I-PHE
from O
a O
chronic B-PHE
cough I-PHE
, O
dry B-PHE
throat I-PHE
and O
thirst B-PHE
. O

Glehnia O
root O
( O
Shashen O
) O
is O
used O
with O
Ophiopogon O
root O
( O
Maidong O
) O
and O
Tendrilled O
fritillary O
bulb O
( O
Chuanbeimu O
) O
. O

2 O
Body O
fluids O
consumed O
by O
febrile B-PHE
diseases I-PHE
manifested O
as O
dry B-PHE
tongue I-PHE
and O
poor B-PHE
appetite I-PHE
. O

Glehnia O
root O
( O
Shashen O
) O
is O
used O
with O
Ophiopogon O
root O
( O
Maidong O
) O
, O
Fresh O
rehmannia O
root O
( O
Shengdihuang O
) O
and O
Fragrant O
solomonseal O
rhizome O
( O
Yuzhu O
) O
in O
the O
formula O
Yiwei O
Tang O
. O

-DOCSTART- O


Lenalidomide O
inhibits O
TNF-alpha B-PHE
production I-PHE
, O
stimulates O
T B-PHE
cells I-PHE
, O
reduces O
serum B-PHE
levels I-PHE
of I-PHE
the I-PHE
cytokines I-PHE
vascular I-PHE
endothelial I-PHE
growth I-PHE
factor I-PHE
( O
VEGF B-PHE
) O
and O
basic B-PHE
fibroblast I-PHE
growth I-PHE
factor I-PHE
( O
bFGF B-PHE
) O
, O
and O
inhibits O
angiogenesis B-PHE
. O

-DOCSTART- O


stop O
bleeding B-PHE
and O
stabilize O
pain B-PHE

-DOCSTART- O


Detection O
of O
primary O
and O
metastatic B-PHE
pheochromocytoma I-PHE
or O
neuroblastoma B-PHE

-DOCSTART- O


insubstantial O
wind B-PHE

-DOCSTART- O


Liver B-PHE
Disease I-PHE

-DOCSTART- O


Acute B-PHE
Exacerbations I-PHE
of I-PHE
Chronic I-PHE
Bronchitis I-PHE

-DOCSTART- O


pulmonary B-PHE
asthenia I-PHE
; O
lung B-PHE
atropy I-PHE
; O
pulmonary B-PHE
flaccidity I-PHE
syndrome I-PHE

-DOCSTART- O


Wind-cold B-PHE
common I-PHE
cold I-PHE
, O
headache B-PHE
, O
cough B-PHE
and O
asthma B-PHE
, O
deep-source B-PHE
nasal I-PHE
congestion I-PHE
, O
cold B-PHE
pain I-PHE
in O
stomach O
duct O
and O
abdomen O
, O
wind-cold-damp B-PHE
impediment I-PHE
, O
cold-damp B-PHE
vaginal I-PHE
discharge I-PHE
, O
dysmenorrhea B-PHE
, O
toxin B-PHE
swelling I-PHE
of I-PHE
sores I-PHE
, O
wind O
papule B-PHE
itching O
. O

-DOCSTART- O


dizziness B-PHE
and O
vertigo B-PHE

-DOCSTART- O


This O
is O
a O
syndrome B-PHE
with I-PHE
numbness I-PHE
and O
a O
pain B-PHE
due O
to O
Wind-Dampness B-PHE
. O

-DOCSTART- O


To O
replenish O
the O
liver B-PHE
and O
kidney B-PHE
, O
improve O
eyesight B-PHE
and O
promote O
the O
growth B-PHE
of I-PHE
black I-PHE
hair I-PHE
. O

-DOCSTART- O


Childhood B-PHE
B I-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


burns B-PHE
; O
fire B-PHE
burns I-PHE

-DOCSTART- O


sparrow B-PHE
vision I-PHE
; O
night B-PHE
blindness I-PHE

-DOCSTART- O


Pheochromocytoma B-PHE

-DOCSTART- O


alleviate O
edema B-PHE

-DOCSTART- O


spinal B-PHE
cord I-PHE
problems I-PHE
, O
pain B-PHE
etc O
. O

-DOCSTART- O


Bofutsushosan O
, O
a O
traditional O
Chinese O
formulation O
, O
prevents O
intimal B-PHE
thickening I-PHE
and O
vascular B-PHE
smooth I-PHE
muscle I-PHE
cell I-PHE
proliferation I-PHE
induced O
by O
balloon O
endothelial B-PHE
denudation I-PHE
in O
rats O
. O

-DOCSTART- O


To O
strengthen O
the O
body B-PHE
resistance I-PHE
to O
consolidate O
the O
constitution O
, O
replenish O
qi O
, O
invigorate O
the O
spleen B-PHE
and O
tonify O
the O
spleen B-PHE
and O
tonify O
the O
kidney B-PHE
to O
relieve O
mental B-PHE
strain I-PHE
. O

-DOCSTART- O


To O
dissipate O
binds O
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


Mucosal B-PHE
Melanoma I-PHE

-DOCSTART- O


latent O
summer B-PHE
heat I-PHE
syndrome I-PHE

-DOCSTART- O


dry B-PHE
mouth I-PHE
; O

xerostomia B-PHE
; O

dryness B-PHE
of I-PHE
mouth I-PHE

-DOCSTART- O


Unresectable O
Metastasis O
Originating O
in O
Colonic B-PHE
Cancer I-PHE
. O

-DOCSTART- O


Croton O
seed O
( O
Badou O
) O
is O
used O
with O
Medicated O
leaven O
( O
Shenqu O
) O
, O
Arisaema O
tuber O
with O
bile O
( O
Dannanxing O
) O
and O
Cinnabar O
( O
Zhusha O
) O
in O
the O
formula O
Baochi O
San O
. O

-DOCSTART- O


warm O
large B-PHE
intestine I-PHE

-DOCSTART- O


absorption B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
motility B-PHE
, O
Others O

-DOCSTART- O


Nausea B-PHE

-DOCSTART- O


Treatment O
of O
loss B-PHE
of I-PHE
consciousness I-PHE
in O
stroke B-PHE
and O
epilepsy B-PHE
, O
sore B-PHE
throat I-PHE
, O
dyspnea B-PHE
and O
cough B-PHE
with O
phlegm B-PHE
difficult O
to O
spit O
out O
, O
constipation B-PHE
, O
external O
use O
for O
subcutaneous B-PHE
pyogenic I-PHE
infections I-PHE
. O

-DOCSTART- O


To O
kill O
roundworms B-PHE
; O

To O
kill O
worms B-PHE
; O

To O
move O
qi O
; O

To O
stop O
pain B-PHE

-DOCSTART- O


There O
are O
two O
isoforms O
of O
ACE O
: O
the O
somatic O
isoform O
, O
which O
exists O
as O
a O
glycoprotein O
comprised O
of O
a O
single O
polypeptide O
chain O
of O
1277 O
; O
and O
the O
testicular B-PHE
isoform I-PHE
, O
which O
has O
a O
lower O
molecular O
mass O
and O
is O
thought O
to O
play O
a O
role O
in O
sperm B-PHE
maturation I-PHE
and O
binding O
of O
sperm B-PHE
to O
the O
oviduct B-PHE
epithelium I-PHE
. O

Somatic O
ACE O
has O
two O
functionally O
active O
domains O
, O
N O
and O
C, O
which O
arise O
from O
tandem O
gene B-PHE
duplication I-PHE
. O

Although O
the O
two O
domains O
have O
high O
sequence O
similarity O
, O
they O
play O
distinct O
physiological O
roles O
. O

The O
C-domain O
is O
predominantly O
involved O
in O
blood B-PHE
pressure I-PHE
regulation I-PHE
while O
the O
N-domain O
plays O
a O
role O
in O
hematopoietic B-PHE
stem I-PHE
cell I-PHE
differentiation I-PHE
and I-PHE
proliferation I-PHE
. O

ACE O
inhibitors O
bind O
to O
and O
inhibit O
the O
activity O
of O
both O
domains O
, O
but O
have O
much O
greater O
affinity O
for O
and O
inhibitory O
activity O
against O
the O
C-domain O
. O

Enalaprilat O
, O
the O
principle O
active B-PHE
metabolite I-PHE
of O
enalapril O
, O
competes O
with O
ATI O
for O
binding O
to O
ACE O
and O
inhibits O
and O
enzymatic B-PHE
proteolysis I-PHE
of O
ATI O
to O
ATII O
. O

Decreasing O
ATII B-PHE
levels I-PHE
in O
the O
body O
decreases O
blood B-PHE
pressure I-PHE
by O
inhibiting O
the O
pressor B-PHE
effects I-PHE
of I-PHE
ATII I-PHE
as O
described O
in O
the O
Pharmacology O
section O
above O
. O

Enalapril O
also O
causes O
an O
increase O
in O
plasma B-PHE
renin I-PHE
activity I-PHE
likely O
due O
to O
a O
loss O
of O
feedback O
inhibition O
mediated O
by O
ATII O
on O
the O
release O
of O
renin B-PHE
and/or O
stimulation O
of O
reflex O
mechanisms O
via O
baroreceptors O
. O

Enalaprilat's O
affinity O
for O
ACE O
is O
approximately O
200000 O
times O
greater O
than O
that O
of O
ATI O
and O
300-1000 O
times O
greater O
than O
that O
enalapril O
. O

-DOCSTART- O


Blockade O
of O
dopaminergic O
D2 O
receptors O
in O
the O
limbic B-PHE
system I-PHE
alleviates O
positive O
symptoms O
of O
schizophrenia B-PHE
such O
as O
hallucinations B-PHE
, O
delusions B-PHE
, O
and O
erratic B-PHE
behavior I-PHE
and O
speech O
. O

Blockade O
of O
serotonergic O
5-HT O
2 O
receptors O
in O
the O
mesocortical B-PHE
tract I-PHE
, O
causes O
an O
excess O
of O
dopamine O
and O
an O
increase O
in O
dopamine O
transmission O
, O
resulting O
in O
an O
increase O
in O
dopamine O
transmission O
and O
an O
elimination O
of O
core O
negative O
symptoms O
. O

Dopamine O
receptors O
in O
the O
nigrostriatal O
pathway O
are O
not O
affected O
by O
risperidone O
and O
extrapyramidal O
effects O
are O
avoided O
. O

Like O
other O
5-HT O
2 O
antagonists O
, O
risperidone O
also O
binds O
at O
alpha(1)-adrenergic O
receptors O
and O
, O
to O
a O
lesser O
extent O
, O
at O
histamine O
H1 O
and O
alpha(2)-adrenergic O
receptors O
. O

-DOCSTART- O


one O
of O
cough B-PHE
that O
gets O
worst O
at O
night O
. O

That O
occurs O
by O
insubstantial O
Fire O
in O
the O
lung O
due O
to O
insufficiency O
of O
the O
kidney O
Eum O

-DOCSTART- O


insufficiency O
of O
heart B-PHE
Gi O

-DOCSTART- O


Stage O
II O
Contiguous O
Adult B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


Heparin O
binds O
to O
antithrombin B-PHE
III I-PHE
to O
form O
a O
heparin-antithrombin O
III O
complex O
. O

-DOCSTART- O


a O
disease O
like O
a O
cholera B-PHE
. O

That O
Has O
a O
abdominal B-PHE
pain I-PHE
, O
vomiting B-PHE
and O
diarrhea B-PHE
caused O
by O
dirty O
and O
acute O
filthy O
Gi O

-DOCSTART- O


lack O
of O
essence O
and O
blood B-PHE

-DOCSTART- O


asthma B-PHE
; O

dyspnea B-PHE
; O

abnormal O
rising O
of O
Gi O
; O

upward O
Gi O
dyspnea O
due O
to O
upward O
adverse O
flow O
of O
the O
lung-Gi O

-DOCSTART- O


Intercritical O
Gout B-PHE

-DOCSTART- O


promote O
sweating B-PHE

-DOCSTART- O


Docetaxel O
binds O
to O
microtubules O
reversibly O
with O
high O
affinity O
, O
which O
stabilises O
microtubules O
and O
prevents O
depolymerisation O
from O
calcium O
ions O
, O
decreased B-PHE
temperature I-PHE
and O
dilution B-PHE
, O
preferentially O
at O
the O
plus O
end O
of O
the O
microtubule O
. O

Irinotecan O
, O
a O
prodrug O
, O
is O
converted O
to O
a O
biologically O
active O
metabolite O
7-ethyl-10-hydroxy-camptothecin O
( O
SN-38 O
) O
by O
a O
carboxylesterase-converting O
enzyme O
. O

SN-38 O
inhibits O
topoisomerase B-PHE
I I-PHE
activity I-PHE
by O
stabilizing O
the O
cleavable O
complex O
between O
topoisomerase B-PHE
I I-PHE
and O
DNA B-PHE
, O
resulting O
in O
DNA B-PHE
breaks I-PHE
that O
inhibit O
DNA B-PHE
replication I-PHE
and O
trigger O
apoptotic B-PHE
cell I-PHE
death I-PHE
. O

-DOCSTART- O


Liver B-PHE
cancer I-PHE

-DOCSTART- O


1 O
Morellic B-PHE
acid I-PHE
, O
one O
of O
its O
components O
, O
inhibits O
Ehrljch-Ascites B-PHE
tumour I-PHE
and O
sarcoma180 B-PHE
. O

2 O
Inhibiting O
BEL-7402 B-PHE
species I-PHE
of O
hepatic B-PHE
cancer I-PHE
cells I-PHE
and O
HeLa B-PHE
cells I-PHE
in O
vitro O
. O

3 O
Increasing O
white B-PHE
blood I-PHE
cells I-PHE
and O
promoting O
its O
phagocytosis B-PHE
during O
the O
treatment O
of O
cancer B-PHE
in O
experimental O
animals O

-DOCSTART- O


heavy B-PHE
eyes I-PHE

-DOCSTART- O


moderate O
sinews B-PHE
and O
bones B-PHE

-DOCSTART- O


deficiency B-PHE
of O
the O
kidney O
; O

deficiency B-PHE
syndrome I-PHE
of O
the O
kidney O
the O
pathological B-PHE
changes I-PHE
due O
to O
deficiency B-PHE
of O
the O
kidney O
essence O
, O
usually O
characterized O
by O
dizziness B-PHE
, O
tinnitus B-PHE
, O
lumbago B-PHE
, O
nocturnal B-PHE
emission I-PHE
, O
impotence B-PHE
, O
lassitude B-PHE
, O
forgetfulness B-PHE
. O

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
t(16;16)(p13.1;q22 O
) O
; O
CBFB-MYH11 O

-DOCSTART- O


Mouth B-PHE
sore I-PHE
, O
clove B-PHE
sore I-PHE
, O
hemorrhoids B-PHE
, O
scrotal B-PHE
eczema I-PHE
, O
bleeding B-PHE
due O
to O
external B-PHE
injury I-PHE
. O

-DOCSTART- O


This O
disease B-PHE
has O
a O
characteristics O
of O
gradual O
onset O
, O
plat O
form O
of O
ulceration B-PHE
, O
mild O
or O
no O
pain B-PHE
, O
no O
change O
of O
skin B-PHE
color I-PHE
or O
dark O
reddish O
or O
blackened O
color O
change O
, O
mild O
or O
no O
fever B-PHE
, O
not O
well O
subsided O
or O
healed O
, O
occasional O
lump B-PHE
formation I-PHE
, O
no O
pus B-PHE
, O
long O
duration O
of O
treatment O
, O
thin O
colourful O
discharge O
, O
Chimse O
and O
weak O
Mac O
. O

-DOCSTART- O


To O
drain O
accumulated O
cold B-PHE
downward O

-DOCSTART- O


As O
first O
clinical O
data O
indicate O
, O
the O
achieved O
blood B-PHE
pressure I-PHE
reduction I-PHE
was O
particularly O
pronounced O
in O
the O
early O
morning O
when O
the O
vaccine O
effect O
suppressed O
the O
naturally O
occurring O
morning O
rise O
in O
blood B-PHE
pressure I-PHE
. O

-DOCSTART- O


Kallmann B-PHE
Syndrome I-PHE

-DOCSTART- O


Hydroflumethiazide O
is O
a O
thiazide O
diuretic O
that O
inhibits O
water B-PHE
reabsorption I-PHE
in O
the O
nephron O
by O
inhibiting O
the O
sodium-chloride B-PHE
symporter I-PHE
( O
SLC12A3 B-PHE
) O
in O
the O
distal O
convoluted O
tubule O
, O
which O
is O
responsible O
for O
0.05 O
of O
total O
sodium B-PHE
reabsorption I-PHE
. O

Normally O
, O
the O
sodium-chloride O
symporter O
transports O
sodium O
and O
chloride O
from O
the O
lumen O
into O
the O
epithelial O
cell O
lining O
the O
distal O
convoluted O
tubule O
. O

The O
energy O
for O
this O
is O
provided O
by O
a O
sodium O
gradient O
established O
by O
sodium-potassium B-PHE
ATPases I-PHE
on O
the O
basolateral B-PHE
membrane I-PHE
. O

Once O
sodium O
has O
entered O
the O
cell O
, O
it O
is O
transported O
out O
into O
the O
basolateral O
interstitium O
via O
the O
sodium-potassium O
ATPase O
, O
causing O
an O
increase O
in O
the O
osmolarity B-PHE
of I-PHE
the I-PHE
interstitium I-PHE
, O
thereby O
establishing O
an O
osmotic B-PHE
gradient I-PHE
for O
water B-PHE
reabsorption I-PHE
. O

By O
blocking O
the O
sodium-chloride B-PHE
symporter I-PHE
, O
Hydroflumethiazide O
effectively O
reduces O
the O
osmotic B-PHE
gradient I-PHE
and O
water B-PHE
reabsorption I-PHE
throughout O
the O
nephron O
. O

-DOCSTART- O


For O
calming O
liver B-PHE
and O
containing O
wind B-PHE

-DOCSTART- O


The O
powder O
of O
Croton O
seed O
( O
Badou O
) O
is O
blown O
into O
the O
throat B-PHE
to O
cause O
vomiting B-PHE
. O

-DOCSTART- O


To O
tonify O
the O
liver B-PHE
and O
the O
kidney B-PHE
, O
to O
strengthen O
the O
tendons B-PHE
and O
bones B-PHE
, O
and O
to O
prevent O
miscarrige B-PHE
. O

-DOCSTART- O


uncomfortable O
of O
the O
heart B-PHE
and O
gallbladder B-PHE

-DOCSTART- O


It O
contains O
about O
0.5 O
of O
fatty O
oil O
, O
exerting O
antitussive O
effect O
. O

-DOCSTART- O


To O
arrest O
seminal B-PHE
emission I-PHE
, O
to O
restrain O
urination B-PHE
, O
and O
to O
check O
diarrhea B-PHE
. O

cturnal B-PHE
emission I-PHE
, O
spermatorrhea B-PHE
, O
enuresis B-PHE
, O
frequent B-PHE
urination I-PHE
, O
abnormal B-PHE
uterine I-PHE
bleeding I-PHE
, O
excessive O
leukorrhea B-PHE
, O
protracted O
diarrhea B-PHE
, O
chronic B-PHE
dysentery I-PHE
. O

-DOCSTART- O


For O
dispelling O
wind-dampness B-PHE
and O
dispersing O
coldness B-PHE
. O

-DOCSTART- O


Indicated O
in O
the O
treatment O
of O
moderate O
to O
severe O
pain B-PHE
. O

Consider O
for O
those O
prone O
to O
constipation B-PHE
or O
respiratory B-PHE
depression I-PHE
. O

Tramadol O
is O
used O
to O
treat O
postoperative O
, O
dental O
, O
cancer B-PHE
, O
and O
acute B-PHE
musculosketetal I-PHE
pain I-PHE
and O
as O
an O
adjuvant O
to O
NSAID O
therapy O
in O
patients O
with O
osteoarthritis B-PHE
. O

-DOCSTART- O


Nevirapine O
binds O
directly O
to O
reverse B-PHE
transcriptase I-PHE
and O
blocks O
the O
RNA-dependent B-PHE
and I-PHE
DNA-dependent I-PHE
DNA I-PHE
polymerase I-PHE
activities O
by O
causing O
a O
disruption B-PHE
of I-PHE
the I-PHE
enzyme's I-PHE
catalytic I-PHE
site I-PHE
. O

-DOCSTART- O


Strengthen O
the O
heart B-PHE
and O
replenish O
qi O
, O
activating O
yang O
and O
blood B-PHE
circulation I-PHE
, O
promoting O
the O
restoration B-PHE
of I-PHE
consciousness I-PHE
with O
drugs O
of O
fragnant O
flavour O
, O
relieving O
pain B-PHE
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk O
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Body B-PHE
weight I-PHE

-DOCSTART- O


aversion O
to O
cold B-PHE
; O

severe B-PHE
chillness I-PHE
; O

creeping B-PHE
chills I-PHE

-DOCSTART- O


Colorectal B-PHE
Cancer I-PHE

-DOCSTART- O


There O
are O
two O
isoforms O
of O
ACE O
: O
the O
somatic O
isoform O
, O
which O
exists O
as O
a O
glycoprotein O
comprised O
of O
a O
single O
polypeptide O
chain O
of O
1277 O
; O
and O
the O
testicular O
isoform O
, O
which O
has O
a O
lower O
molecular O
mass O
and O
is O
thought O
to O
play O
a O
role O
in O
sperm B-PHE
maturation I-PHE
and O
binding O
of O
sperm O
to O
the O
oviduct O
epithelium O
. O

Somatic O
ACE O
has O
two O
functionally O
active O
domains O
, O
N O
and O
C, O
which O
arise O
from O
tandem O
gene O
duplication O
. O

Although O
the O
two O
domains O
have O
high O
sequence O
similarity O
, O
they O
play O
distinct O
physiological O
roles O
. O

The O
C-domain O
is O
predominantly O
involved O
in O
blood B-PHE
pressure I-PHE
regulation I-PHE
while O
the O
N-domain O
plays O
a O
role O
in O
hematopoietic O
stem O
cell O
differentiation O
and O
proliferation O
. O

ACE O
inhibitors O
bind O
to O
and O
inhibit O
the O
activity O
of O
both O
domains O
, O
but O
have O
much O
greater O
affinity O
for O
and O
inhibitory O
activity O
against O
the O
C-domain O
. O

Quinaprilat O
, O
the O
principle O
active O
metabolite O
of O
quinapril O
, O
competes O
with O
ATI O
for O
binding O
to O
ACE O
and O
inhibits O
and O
enzymatic O
proteolysis O
of O
ATI O
to O
ATII O
. O

Decreasing O
ATII O
levels O
in O
the O
body O
decreases O
blood B-PHE
pressure I-PHE
by O
inhibiting O
the O
pressor O
effects O
of O
ATII O
as O
described O
in O
the O
Pharmacology O
section O
above O
. O

Quinaprilat O
also O
causes O
an O
increase O
in O
plasma O
renin O
activity O
likely O
due O
to O
a O
loss O
of O
feedback O
inhibition O
mediated O
by O
ATII O
on O
the O
release O
of O
renin O
and/or O
stimulation O
of O
reflex O
mechanisms O
via O
baroreceptors O
. O

-DOCSTART- O


The O
role O
of O
crude O
polysaccharide O
fractions O
on O
the O
mitogenic B-PHE
activity I-PHE
by O
Shosaikoto O
. O

-DOCSTART- O


dyspnea B-PHE
and O
tachypnea B-PHE
; O

shortness B-PHE
of I-PHE
breath I-PHE

-DOCSTART- O


A O
symptom O
that O
the O
lung O
is O
blocked O
up O
caused O
by O
symptoms O
due O
to O
retention B-PHE
of I-PHE
phlegm I-PHE
. O

-DOCSTART- O


Anesthesia B-PHE
With O
Use O
of O
LMA O
( O
Laryngeal O
Mask O
Airway O
) O

-DOCSTART- O


cough B-PHE
with I-PHE
blood I-PHE
due O
to O
a O
damaged B-PHE
lungs I-PHE
because O
of O
exhaustion B-PHE
syndrome I-PHE

-DOCSTART- O


To O
nourish O
yin O
and O
moisterize O
lung B-PHE
; O

To O
suppress O
fire O
and O
desolve O
phlegm B-PHE

-DOCSTART- O


carbuncle B-PHE
and O
cellulitis B-PHE

-DOCSTART- O


impetigo B-PHE
; O
pyoderma B-PHE

-DOCSTART- O


having O
painful B-PHE
and I-PHE
benumbed I-PHE
joint I-PHE

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Megakaryoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


desire O
for O
vomiting B-PHE
; O
feel O
nauseated B-PHE
; O
nausea B-PHE

-DOCSTART- O


For O
the O
treatment O
of O
adult O
patients O
diagnosed O
with O
anaplastic B-PHE
astrocytoma I-PHE
whose O
disease O
has O
progressed O
after O
therapy O
with O
nitrosourea O
and O
procarbazine O
, O
as O
well O
as O
concomitantly O
with O
radiation O
therapy O
for O
treatment O
of O
newly O
diagnosed O
glioblastoma B-PHE
multiforme I-PHE
. O
Also O
used O
as O
maintenance O
therapy O
for O
glioblastoma B-PHE
multiforme I-PHE
. O

-DOCSTART- O


amenorrhea B-PHE

-DOCSTART- O


acute B-PHE
appendicitis I-PHE
; O
periappendicular B-PHE
abscess I-PHE
; O
intestinal B-PHE
carbuncle I-PHE
; O
intestinal B-PHE
abscess I-PHE

-DOCSTART- O


Treatment O
of O
jaundice B-PHE
caused O
by O
damp-heat B-PHE
, O
heat B-PHE
stroke I-PHE
with O
diarrhea B-PHE
, O
urolithiasis B-PHE
and O
hematuria B-PHE
, O
carbuncles B-PHE
and O
boils B-PHE
, O
traumatic B-PHE
injuries I-PHE
. O

-DOCSTART- O


epistaxis B-PHE

-DOCSTART- O


Indacaterol O
works O
by O
stimulating O
adrenergic O
beta-2 O
receptors O
in O
the O
smooth O
muscle O
of O
the O
airways O
. O

Tiotropium O
is O
a O
muscarinic O
receptor O
antagonist O
, O
often O
referred O
to O
as O
an O
antimuscarinic O
or O
anticholinergic O
agent O
. O

-DOCSTART- O


Quality O
of O
life O
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Others O
, O
Protective B-PHE
immunity I-PHE
, O
Inflammation B-PHE

-DOCSTART- O


Traumatic B-PHE
brain I-PHE
injury I-PHE

-DOCSTART- O


Follicular B-PHE
Lymphoma I-PHE

-DOCSTART- O


Rikkunshito O
( O
RKT O
) O
, O
a O
Japanese O
traditional O
medicine O
, O
has O
been O
shown O
to O
stimulate O
food O
intake O
in O
rats O
with O
cisplatin-induced B-PHE
anorexia I-PHE
; O
however O
, O
the O
underlying O
mechanisms O
remain O
unknown O
. O

In O
this O
study O
, O
we O
investigated O
whether O
RKT O
is O
involved O
in O
the O
degradation O
of O
peripheral B-PHE
ghrelin I-PHE
. O

RKT O
inhibited O
decreases O
in O
plasma B-PHE
ghrelin I-PHE
level I-PHE
and O
enhanced O
acyl- B-PHE
to I-PHE
desacyl-ghrelin I-PHE
( O
A/D B-PHE
) O
ratio O
in O
cisplatin-treated O
rats O
. O

Several O
components O
of O
RKT O
demonstrated O
inhibitory O
activity O
against O
ghrelin B-PHE
deacylating I-PHE
enzymes I-PHE
. O

In O
addition O
, O
10-gingerol O
, O
a O
component O
of O
RKT O
, O
inhibited O
exogenous O
ghrelin B-PHE
deacylation I-PHE
. O

Therefore O
, O
RKT O
may O
enhance O
plasma B-PHE
acyl I-PHE
- I-PHE
ghrelin I-PHE
level I-PHE
, O
at O
least O
in O
part O
, O
by O
inhibiting O
the O
circulating O
ghrelin B-PHE
degrading I-PHE
enzyme I-PHE
. O

-DOCSTART- O


disperse O
wind B-PHE
and O
eliminate O
dampness B-PHE

-DOCSTART- O


extinguish O
wind B-PHE
and O
stabilize O
fright B-PHE

-DOCSTART- O


invigorate O
blood B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


To O
disperse O
accumulation O
, O
disinhibit O
diaphragm B-PHE
, O
precipitate O
heat B-PHE
toxin I-PHE
. O

-DOCSTART- O


Kampo O
( O
traditional O
Japanese O
herbal O
) O
medicines O
are O
taken O
orally O
due O
to O
which O
the O
gastric B-PHE
mucosal I-PHE
immune I-PHE
system I-PHE
may O
act O
as O
one O
of O
the O
major O
targets O
for O
the O
expression O
of O
pharmacological O
activity O
. O

The O
inner O
surface O
of O
the O
intestinal O
tract O
possesses O
a O
large O
area O
of O
mucosal O
membranes O
, O
and O
the O
intestinal O
epithelial O
cells O
sit O
at O
the O
interface O
between O
a O
lumen O
and O
a O
lymphocyte O
- O
rich O
lamina O
propria O
. O

The O
cross O
talk O
that O
occurs O
between O
these O
compartments O
serves O
to O
maintain O
intestinal B-PHE
homeostasis I-PHE
, O
and O
the O
cytokine B-PHE
network I-PHE
plays O
an O
important O
role O
in O
the O
cross O
talk O
. O

In O
this O
study O
, O
the O
effect O
of O
Hochuekkito O
( O
HET O
) O
, O
one O
of O
Kampo O
medicines O
, O
on O
cytokine B-PHE
secretion I-PHE
of O
intestinal O
epithelial O
cells O
was O
investigated O
. O

When O
murine O
normal O
colonic O
epithelial O
cell O
- O
line O
MCE301 B-PHE
cells I-PHE
were O
stimulated O
with O
HET O
, O
the O
contents O
of O
granulocyte B-PHE
colony I-PHE
- I-PHE
stimulating I-PHE
factor I-PHE
( O
G B-PHE
- I-PHE
CSF I-PHE
) O
in O
the O
conditioned O
medium O
were O
significantly O
increased O
in O
dose O
- O
and O
time O
- O
dependent O
manners O
. O

The O
enhanced O
G B-PHE
- I-PHE
CSF I-PHE
gene I-PHE
transcription I-PHE
in O
MCE301 O
cells O
by O
the O
stimulation O
of O
HET O
was O
observed O
by O
RT O
- O
PCR O
. O

The O
enhanced O
G B-PHE
- I-PHE
G-CSF I-PHE
secretion I-PHE
by O
HET O
was O
also O
observed O
in O
C3H O
/ O
HeJ O
mice O
- O
derived O
primary O
cultured O
colonic O
epithelial O
cells O
. O

When O
the O
HET O
was O
fractionated O
, O
only O
the O
polysaccharide B-PHE
fraction I-PHE
( O
F B-PHE
- I-PHE
5 I-PHE
) O
enhanced O
the O
G B-PHE
- I-PHE
CSF I-PHE
secretion I-PHE
of O
MCE301 O
cells O
, O
and O
the O
activity O
of O
F B-PHE
- I-PHE
5 I-PHE
lost O
after O
the O
treatment O
of O
periodate O
that O
can O
degrade O
the O
carbohydrate O
moiety O
. O

These O
results O
suggest O
that O
HET O
enhances O
secretion B-PHE
of I-PHE
G I-PHE
- I-PHE
CSF I-PHE
from O
colonic O
epithelial O
cells O
and O
the O
polysaccharide O
is O
one O
of O
the O
active O
ingredients O
of O
HET O
. O

The O
enhanced O
G B-PHE
- I-PHE
CSF I-PHE
secretion I-PHE
by O
HET O
may O
partly O
contribute O
to O
the O
clinically O
observed O
various O
pharmacological O
activities O
of O
HET O
including O
immunomodulating B-PHE
activity I-PHE
. O

-DOCSTART- O


accumulation O
of O
pathogenic B-PHE
factors I-PHE
in O
the O
chest O
; O
accumulation O
of O
pathogens B-PHE
in O
the O
chest O
; O
knotted B-PHE
chest I-PHE
a O
syndrome O
due O
to O
accumulation O
of O
pathogenic O
heat B-PHE
or O
cold B-PHE
with O
stagnancy B-PHE
of I-PHE
fluid I-PHE
or O
phlegm B-PHE
or O
blood B-PHE
in O
the O
chest O
. O

-DOCSTART- O


Acute B-PHE
otitis I-PHE
media I-PHE
in O
children O
that O
is O
caused O
by O
susceptible O
strains O
of O
Haemophilus B-PHE
influenzae I-PHE
. O

-DOCSTART- O


To O
promote O
blood B-PHE
circulation I-PHE
, O
remove O
blood B-PHE
stasis I-PHE
, O
restore O
consciousness B-PHE
, O
remove O
obstruction B-PHE
in O
the O
channels O
, O
suppress O
the O
hyperfunction O
of O
liver-yang O
and O
stop O
endogenous B-PHE
wind I-PHE
to O
relieve O
convulsion B-PHE
. O

-DOCSTART- O


Renal B-PHE
Impairment I-PHE

-DOCSTART- O


Knocks B-PHE
and O
falls B-PHE
, O
stasis B-PHE
swelling I-PHE
pain I-PHE
, O
wind-damp B-PHE
impediment I-PHE
pain I-PHE
. O

-DOCSTART- O


Pectus B-PHE
Excavatum I-PHE

-DOCSTART- O


End B-PHE
Stage I-PHE
Renal I-PHE
Disease I-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Digestion B-PHE
, O
Energy O
/ O
food O
intake O
( O
apetite O
/ O
satiety O
) O
, O
Physical B-PHE
performance B-PHE
and O
fitness B-PHE
, O
Body B-PHE
fat I-PHE
deposition I-PHE
( O
total O
amount O

-DOCSTART- O


Chronic B-PHE
Kidney I-PHE
Disease I-PHE

-DOCSTART- O


To O
regulate O
qi O
, O
promote O
blood B-PHE
circulation I-PHE
and O
regulate O
menstruation B-PHE
. O

-DOCSTART- O


concurrent O
disease B-PHE
of O
the O
T'aeyang O
meridian O
and O
the O
Soyang O
meridian O

-DOCSTART- O


soothe O
diaphragm B-PHE

-DOCSTART- O


Stagnation O
of O
liver-qi O
, O
abnormal O
relation O
between O
spleen O
and O
stomach O
, O
sensation B-PHE
of I-PHE
fullness I-PHE
and O
obstruction B-PHE
over O
chest O
and O
diaphragm O
, O
distension B-PHE
at O
hypochondriac O
regions O
, O
stomach-ache B-PHE
, O
gastric B-PHE
upset I-PHE
, O
eructation B-PHE
, O
acid B-PHE
eructation I-PHE
, O
nausea B-PHE
and O
vomiting B-PHE
. O

-DOCSTART- O


Psychomotor B-PHE
Agitation I-PHE

-DOCSTART- O


Anemia B-PHE
in I-PHE
Chronic I-PHE
Renal I-PHE
Disease I-PHE

-DOCSTART- O


( O
1 O
) O
pestilent B-PHE
lesions I-PHE
; O
leprosy B-PHE
( O
2 O
) O
malignant B-PHE
furuncle I-PHE

-DOCSTART- O


To O
soothe O
liver B-PHE
and O
clear O
heat B-PHE
; O
To O
constrain O
qi O
and O
strengthen O
spleen B-PHE
; O
To O
calm O
spirit B-PHE

-DOCSTART- O


Stage O
IV O
Adult B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


Ascites B-PHE
. O

Croton O
seed O
( O
Badou O
) O
is O
used O
with O
Apricot O
seed O
( O
Xingren O
) O
. O

-DOCSTART- O


Indicated O
as O
symptomatic O
treatment O
of O
allergic B-PHE
reactions I-PHE
: O
urticaria B-PHE
, O
allergies B-PHE
of I-PHE
the I-PHE
upper I-PHE
respiratory I-PHE
tract I-PHE
such O
as O
hey B-PHE
fever I-PHE
and O
perennial B-PHE
rhinitis I-PHE
, O
food B-PHE
and I-PHE
drug I-PHE
allergies I-PHE
; O
pruritus B-PHE
of I-PHE
various I-PHE
origins I-PHE
, O
except O
pruritus B-PHE
due O
to O
cholestasis B-PHE
; O
insect B-PHE
bites I-PHE
. O

-DOCSTART- O


be O
torn O
of O
sore O
toxic O
pathogenic O
factor O

-DOCSTART- O


Aortic B-PHE
Valve I-PHE
Stenosis I-PHE

-DOCSTART- O


Pulmonary B-PHE
Arterial I-PHE
Hypertension I-PHE

-DOCSTART- O


Intraabdominal B-PHE
Infections I-PHE

-DOCSTART- O


relieve O
cough B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
absorption O
, O
Lipid O
profile O
, O
DietNArelated O
cardiovascular B-PHE
disease I-PHE
, O
motility O
, O
Evacuation O

-DOCSTART- O


a O
continuum O
of O
pus B-PHE
and O
blood B-PHE
due O
to O
the O
parasite O
in O
the O
ear O

-DOCSTART- O


steaming B-PHE
bone I-PHE
disorder I-PHE

-DOCSTART- O


stranguria B-PHE
due O
to O
urinary B-PHE
stone I-PHE
; O
dysuria B-PHE
caused O
by O
urinary B-PHE
stone I-PHE
; O
stranguria B-PHE
due O
to O
urolithiasis B-PHE
; O
stony B-PHE
dysuria I-PHE
; O
dysuria B-PHE
caused O
by O
calculi B-PHE

-DOCSTART- O


ThioTEPA O
is O
used O
a O
as O
conditioning O
treatment O
prior O
to O
allogeneic O
or O
autologous O
haematopoietic O
progenitor O
cell O
transplantation O
( O
HPCT O
) O
in O
haematological B-PHE
diseases I-PHE
in O
adult O
and O
paediatric O
patients O
. O

Also O
, O
when O
high O
dose O
chemotherapy O
with O
HPCT O
support O
it O
is O
appropriate O
for O
the O
treatment O
of O
solid B-PHE
tumours I-PHE
in O
adult O
and O
paediatric O
patients O
. O

-DOCSTART- O


To O
benefit O
vital O
Qi O
, O
invigorate O
the O
spleen B-PHE
and O
nourish O
the O
stomach B-PHE
. O

For O
hypofunction B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
stomach I-PHE
, O
peptic B-PHE
ulcer I-PHE
and O
chronic B-PHE
gastritis I-PHE
. O

Recently O
, O
also O
used O
for O
the O
cancers B-PHE
of I-PHE
erophagus I-PHE
, I-PHE
stomach I-PHE
and I-PHE
intestines I-PHE
. O

-DOCSTART- O


heat B-PHE
in O
the O
stomach O
; O

stomach B-PHE
heat I-PHE
; O

stomach B-PHE
affected O
by O
heat B-PHE
impairment I-PHE
of O
the O
stomach O
by O
pathogenic B-PHE
heat I-PHE
or O
taking O
excessive O
heat-producing O
food O
, O
marked O
by O
thirst B-PHE
, O
halitosis B-PHE
, O
hyperorexia B-PHE
, O
oliguria B-PHE
with O
dark B-PHE
urine I-PHE
, O
constipation B-PHE
or O
even O
ulceration B-PHE
of O
the O
mouth O
, O
gingivitis B-PHE
. O

-DOCSTART- O


To O
stop O
pain B-PHE

-DOCSTART- O


promote O
the O
large B-PHE
intestine I-PHE

-DOCSTART- O


The O
large O
hydrophilic O
molecule O
is O
able O
to O
form O
hydrogen O
bond O
interactions O
with O
the O
terminal O
D-alanyl-D-alanine O
moieties O
of O
the O
NAM/NAG-peptides O
, O
which O
is O
normally O
a O
five-point O
interaction O
. O

-DOCSTART- O


Eyebrow B-PHE
Hypotrichosis I-PHE

-DOCSTART- O


clear O
heat B-PHE
and O
dry O
dampness B-PHE

-DOCSTART- O


cool O
the O
heart B-PHE

-DOCSTART- O


Valproic O
Acid O
acts O
by O
increasing O
gamma-aminobutyric B-PHE
acid I-PHE
levels I-PHE
in O
the O
brain O
or O
by O
altering O
the O
properties O
of O
voltage O
dependent O
sodium O
channels O
. O

Lamotrigine O
inhibits O
voltage-sensitive O
sodium O
channels O
and/or O
calcium O
channels O
, O
thereby O
stabilizing O
neuronal B-PHE
membranes I-PHE
and O
consequently O
modulating O
presynaptic O
transmitter O
release O
of O
excitatory O
amino O
acids O
. O

-DOCSTART- O


To O
resolve O
exterior O
, O
eliminate O
damp B-PHE
, O
relieve O
cough B-PHE
and O
calm O
asthma B-PHE
. O

-DOCSTART- O


Locally O
acting O
as O
an O
irritant O
for O
skin O
and O
mucosa O
; O
orally O
as O
a O
potent O
purgative O
. O

-DOCSTART- O


To O
relieve O
cough B-PHE
and O
dyspnea B-PHE
, O
and O
eliminate O
retained O
phlegm B-PHE
. O

-DOCSTART- O


Inhibitory O
effect O
of O
Chunghyuldan O
in O
prostaglandin O
E2 O
and O
nitric O
oxide O
biosynthesis O
of O
lipopolysaccharide-induced O
RAW O
264.7 O
cells O
. O

-DOCSTART- O


clear O
the O
lung B-PHE

-DOCSTART- O


Endocrine B-PHE
system I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Eldery O
, O
Woman O
, O
Menopausal B-PHE
woman I-PHE

-DOCSTART- O


pyogenic B-PHE
infections I-PHE
due O
to O
furuncle B-PHE

-DOCSTART- O


Norepinephrine O
functions O
as O
a O
peripheral O
vasoconstrictor O
by O
acting O
on O
alpha-adrenergic O
receptors O
. O

It O
is O
also O
an O
inotropic O
stimulator O
of O
the O
heart B-PHE
and O
dilator O
of O
coronary B-PHE
arteries I-PHE
as O
a O
result O
of O
it's O
activity O
at O
the O
beta-adrenergic O
receptors O
. O

-DOCSTART- O


Neurocognitive B-PHE
Function I-PHE
. O

-DOCSTART- O


stop O
diarrhea B-PHE

-DOCSTART- O


After O
binding O
to O
HER2 O
on O
the O
tumor B-PHE
cell I-PHE
surface O
, O
trastuzumab O
induces O
an O
antibody-dependent B-PHE
cell-mediated I-PHE
cytotoxicity I-PHE
against O
tumor B-PHE
cells I-PHE
that O
overexpress O
HER2 B-PHE
. O

Epirubicin O
intercalates O
into O
DNA O
and O
interacts O
with O
topoisomerase B-PHE
II I-PHE
, O
thereby O
inhibiting O
DNA B-PHE
replication I-PHE
and O
repair O
and O
RNA O
and O
protein B-PHE
synthesis I-PHE
. O

-DOCSTART- O


sudden O
turmoil B-PHE
; O

cholera B-PHE
disease I-PHE
; O

acute B-PHE
gastroenteritis I-PHE
; O

acute B-PHE
vomiting I-PHE
and O
diarrhea B-PHE
a O
group O
of O
diseases B-PHE
including O
cholera B-PHE
, O
characterized O
by O
sudden O
and O
drastic O
vomiting B-PHE
and O
diarrhea B-PHE
. O

-DOCSTART- O


This O
is O
running O
a O
fever B-PHE
due O
to O
epidemic B-PHE
. O

-DOCSTART- O


Mild O
Asthma B-PHE

-DOCSTART- O


Ramipril O
is O
an O
angiotensin-converting O
enzyme O
inhibitor O
, O
used O
to O
treat O
high B-PHE
blood I-PHE
pressure I-PHE
and O
congestive B-PHE
heart I-PHE
failure I-PHE
. O

Irbesartan O
, O
by O
blocking O
the O
binding O
of O
angiotensin O
II O
to O
the O
AT1 O
receptor O
, O
promotes O
vasodilation B-PHE
and O
decreases O
the O
effects B-PHE
of I-PHE
aldosterone I-PHE
. O

-DOCSTART- O


Treatment O
of O
wind-heat B-PHE
type O
common O
cold B-PHE
, O
headache B-PHE
and O
dizziness B-PHE
, O
inflammation B-PHE
of O
the O
eye O
, O
blurred B-PHE
vision I-PHE
. O

-DOCSTART- O


Tiotropium O
is O
a O
muscarinic O
receptor O
antagonist O
, O
often O
referred O
to O
as O
an O
antimuscarinic O
or O
anticholinergic O
agent O
. O

Although O
it O
does O
not O
display O
selectivity O
for O
specific O
muscarinic O
receptors O
, O
on O
topical O
application O
it O
acts O
mainly O
on O
M3 O
muscarinic O
receptors O
located O
in O
the O
airways O
to O
produce O
smooth O
muscle B-PHE
relaxation I-PHE
, O
thus O
producing O
a O
bronchodilatory B-PHE
effect I-PHE
. O

-DOCSTART- O


To O
clear O
heat B-PHE
and O
dry O
damp B-PHE
, O
check O
dysentery B-PHE
. O

-DOCSTART- O


lumbago B-PHE
due O
to O
strain B-PHE
and O
contusion B-PHE

-DOCSTART- O


stiffness B-PHE
of O
four O
ends O

-DOCSTART- O


This O
is O
a O
syndrome O
with O
ooze O
from O
a O
sore B-PHE
. O

-DOCSTART- O


a O
disease O
that O
difficult O
to O
sleep O
, O
beating O
fast O
in O
the O
chest O
, O
feel O
anxiety B-PHE
, O
sometimes O
frightening B-PHE
well O
due O
to O
cold B-PHE
of O
gallbladder B-PHE
meridian I-PHE

-DOCSTART- O


Airway O
Reflexes O
, O
Protective O

-DOCSTART- O


the O
symptom O
caused O
by O
stagnation O
of O
phlegm-heat B-PHE

-DOCSTART- O


For O
acute O
and O
long-term O
management O
of O
signs O
and O
symptoms O
of O
osteoarthritis B-PHE
and O
rheumatoid B-PHE
arthritis I-PHE
, O
as O
well O
as O
for O
the O
management O
of O
pain B-PHE
. O

-DOCSTART- O


Used O
in O
the O
treatment O
of O
relapsing O
forms O
of O
multiple B-PHE
sclerosis I-PHE
( O
MS B-PHE
) O
. O

-DOCSTART- O


Treatment O
of O
cough B-PHE
, O
asthma B-PHE
and O
distending B-PHE
pain I-PHE
of O
the O
chest O
caused O
by O
cold B-PHE
phlegm I-PHE
, O
arthralgia B-PHE
accompanied O
by O
numbness B-PHE
due O
to O
obstruction O
of O
collaterals O
by O
phlegm B-PHE
, O
deep O
abscess B-PHE
. O

-DOCSTART- O


Exposure O
to O
Hepatitis B-PHE
B I-PHE
Virus I-PHE

-DOCSTART- O


alleviate O
edema B-PHE
and O
relieve O
toxicity B-PHE

-DOCSTART- O


Proellex O
selectively O
blocks O
the O
progesterone O
receptor O
thus O
avoiding O
the O
adverse O
effects O
of O
GnRH O
agonists O
associated O
with O
the O
induction O
of O
a O
low O
estrogen B-PHE
, O
menopausal-like B-PHE
state O
in O
women O
. O

-DOCSTART- O


reinforce O
bone B-PHE
marrow I-PHE

-DOCSTART- O


a O
symptom O
of O
not B-PHE
vomiting I-PHE
despite O
nausea B-PHE

-DOCSTART- O


To O
remove O
blood B-PHE
stasis I-PHE
and O
promote O
the O
blood B-PHE
flow I-PHE
, O
to O
stimulate O
menstrual B-PHE
discharge I-PHE
, O
and O
to O
induce O
labour O
. O

-DOCSTART- O


a O
disease B-PHE
with O
pain B-PHE
and O
cold B-PHE
in O
the O
joints O

-DOCSTART- O


To O
expel O
wind B-PHE
from O
the O
body O
surface O
, O
clear O
away O
heat B-PHE
and O
promote O
bowel B-PHE
movement I-PHE
. O

-DOCSTART- O


Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Overall O
CVD B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
quicken O
blood B-PHE
and O
resolve O
toxin B-PHE
. O

-DOCSTART- O


For O
for O
use O
with O
insulin O
for O
the O
treatment O
of O
noninsulin-dependent O
( O
type O
2 O
) O
diabetes B-PHE
mellitus I-PHE
. O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Eldery O
, O
Endocrine B-PHE
system I-PHE
, O
Intelligence B-PHE
, O
Others O
, O
Memory B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


To O
stimulate O
digestion B-PHE
and O
promote O
the O
functional O
activity B-PHE
of I-PHE
the I-PHE
stomach I-PHE
; O
to O
improve O
the O
normal O
flow O
of O
qi O
and O
dissipate O
blood B-PHE
stasis I-PHE
. O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
angioedema B-PHE
. O

-DOCSTART- O


Kidney O
Transplant O

-DOCSTART- O


pectoral B-PHE
pain I-PHE
with O
stuffiness B-PHE
; O
chest B-PHE
impediment I-PHE
; O
chest B-PHE
blockage I-PHE
; O
obstruction O
of O
Gi O
in O
the O
chest O
( O
1 O
) O
a O
morbid B-PHE
condition I-PHE
due O
to O
stagnation B-PHE
of B-PHE
dampness B-PHE
and O
phlegm B-PHE
, O
marked O
by O
choking B-PHE
pain I-PHE
in O
the O
chest O
, O
sometimes O
referring O
to O
the O
back B-PHE
, O
usually O
accompanied O
by O
shortness B-PHE
of I-PHE
breath I-PHE
, O
cough B-PHE
. O
( O

2 O
) O
obstruction O
of O
Gi O
in O
the O
stomach O
, O
chest B-PHE
pain I-PHE
that O
occurs O
immediately O
after O
eating O
, O
accompanied O
by O
difficulty B-PHE
in I-PHE
swallowing I-PHE
and O
frequent O
vomiting B-PHE
. O

-DOCSTART- O


phlegm B-PHE
; O
sputum B-PHE
pathologic O
mucoid O
substances O
collected O
in O
a O
diseased O
organ O
or O
tissue O
. O

-DOCSTART- O


IMC-A12 O
is O
a O
fully O
human O
monoclonal O
antibody O
that O
specifically O
targets O
the O
type O
1 O
human O
insulin-like O
growth O
factor O
receptor O
( O
IGF-IR O
) O
. O

Tumors B-PHE
have O
receptors O
for O
the O
insulin-like O
growth O
factor-1 O
( O
IGF-I O
) O
, O
and O
it O
is O
thought O
that O
the O
presence O
of O
these O
receptors O
cause O
tumors B-PHE
to O
grow O
. O

IMC-A12 O
attaches O
to O
the O
receptors O
and O
may O
inhibit O
the O
growth B-PHE
of I-PHE
cancer I-PHE
cells I-PHE
. O

-DOCSTART- O


epidemic B-PHE
smallpox I-PHE

-DOCSTART- O


scabies B-PHE

-DOCSTART- O


Urinary B-PHE
Bladder I-PHE
, I-PHE
Overactive I-PHE

-DOCSTART- O


Neurological B-PHE
systems I-PHE
health I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE
, O
Diet O
related O
cardiovascular B-PHE
disease I-PHE
, O
Memory B-PHE
, O
Neurological B-PHE
systems I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


cough B-PHE
due O
to O
pulmonary B-PHE
flaccidity I-PHE

-DOCSTART- O


cough B-PHE
due O
to O
phlegm-damp B-PHE
due O
to O
lung-heat B-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Monocytic I-PHE
Leukemia I-PHE

-DOCSTART- O


Proteinuria B-PHE

-DOCSTART- O


Overactive B-PHE
Bladder I-PHE

-DOCSTART- O


chronic B-PHE
cough I-PHE
due O
to O
deficiency B-PHE
of I-PHE
the I-PHE
lung I-PHE

-DOCSTART- O


Purging B-PHE
by O
aggression O

-DOCSTART- O


Enfuvirtide O
binds O
to O
the O
first O
heptad-repeat B-PHE
( O
HR1 O
) O
in O
the O
gp41 O
subunit O
of O
the O
viral O
envelope O
glycoprotein O
and O
prevents O
the O
conformational B-PHE
changes I-PHE
required O
for O
the O
fusion O
of O
viral O
and O
cellular B-PHE
membranes I-PHE
. O

It O
works O
by O
disrupting O
the O
HIV-1 B-PHE
molecular I-PHE
machinery I-PHE
at O
the O
final O
stage O
of O
fusion O
with O
the O
target O
cell O
, O
preventing O
uninfected B-PHE
cells I-PHE
from O
becoming O
infected O
. O

Enfuvirtide O
is O
a O
biomimetic O
peptide O
that O
was O
rationally O
designed O
to O
mimic O
components O
of O
the O
HIV-1 B-PHE
fusion I-PHE
machinery O
and O
displace O
them O
, O
preventing O
normal O
fusion B-PHE
. O

-DOCSTART- O


Rituximab O
binds O
to O
the O
CD20 O
antigen O
on O
B O
lymphocytes O
, O
while O
the O
Fc O
domain O
recruits O
antibodies B-PHE
and O
complements O
to O
mediate O
cell B-PHE
lysis I-PHE
and O
interferes O
with O
the O
growth O
and O
spread O
of O
cancer B-PHE
cells I-PHE
in O
the O
body O
. O

-DOCSTART- O


For O
palliative O
, O
not O
definitive O
, O
therapy O
to O
temporarily O
maintain O
the O
patency B-PHE
of I-PHE
the I-PHE
ductus I-PHE
arteriosus I-PHE
until O
corrective O
or O
palliative O
surgery O
can O
be O
performed O
in O
neonates O
who O
have O
congenital B-PHE
heart I-PHE
defects I-PHE
and O
who O
depend O
upon O
the O
patent O
ductus O
for O
survival O
. O

Also O
for O
the O
treatment O
of O
erectile B-PHE
dysfunction I-PHE
due O
to O
neurogenic O
, O
vasculogenic O
, O
psychogenic O
, O
or O
mixed O
etiology O
. O

-DOCSTART- O


to O
have O
skin B-PHE
rashes I-PHE
due O
to O
epidemic B-PHE
febrile I-PHE

-DOCSTART- O


Treatment O
of O
ulcer B-PHE
difficulty O
to O
heal O
, O
wounds B-PHE
, O
burns B-PHE
and O
scalds B-PHE
. O

-DOCSTART- O


reinforce O
the O
spleen B-PHE

-DOCSTART- O


This O
means O
no O
rash B-PHE
formation O
after O
days O
of O
fever B-PHE
. O

-DOCSTART- O


constipation B-PHE
and O
dry B-PHE
stool I-PHE

-DOCSTART- O


relieve O
spasm B-PHE

-DOCSTART- O


moisten O
the O
lung B-PHE

-DOCSTART- O


Hepatitis B-PHE
C I-PHE
, I-PHE
Chronic I-PHE

-DOCSTART- O


convulsive B-PHE
seizure I-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
stuffiness B-PHE
and O
hot B-PHE
in O
the O
chest O
and O
abdomen O
. O

-DOCSTART- O


Treatment O
of O
thrist O
in O
febrile B-PHE
disease I-PHE
, O
dry B-PHE
cough I-PHE
due O
to O
heat B-PHE
in O
the O
lung O
, O
diabetes B-PHE
caused O
by O
internal O
heat B-PHE
, O
sores B-PHE
and O
abscess B-PHE
. O

-DOCSTART- O


Stage O
II O
Childhood B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


reinforce O
Gi(Qi O
) O
and O
blood B-PHE

-DOCSTART- O


The O
so O
called O
renin-angiotensin B-PHE
system I-PHE
( O
RAS B-PHE
) O
is O
an O
important O
regulator O
of O
blood B-PHE
pressure I-PHE
and O
has O
already O
been O
successfully O
targeted O
by O
three O
major O
classes O
of O
antihypertensive O
drugs O
: O
by O
ACE O
inhibitors O
, O
by O
ARBs O
and O
by O
renin O
inhibitors O
. O
QQQQQ O
-DOCSTART- O


lack O
of O
Gi O
; O

asthenic B-PHE
breathing I-PHE
a O
morbid B-PHE
condition I-PHE
chiefly O
manifested O
as O
disinclination B-PHE
ta1k O
, O
low B-PHE
voice I-PHE
, O
listlessness B-PHE
and O
asthenia B-PHE
, O
lack B-PHE
of I-PHE
strength I-PHE
in O
speaking O
, O
weak O
pulse B-PHE

-DOCSTART- O


Lung B-PHE
cancer I-PHE

-DOCSTART- O


Myocardial B-PHE
Reperfusion I-PHE
Injury I-PHE

-DOCSTART- O


Therapeutic O
effect O
of O
Kakkonto O
in O
a O
mouse O
model O
of O
food B-PHE
allergy I-PHE
with O
gastrointestinal O
symptoms O
. O

-DOCSTART- O


Heroin O
is O
a O
mu-opioid O
agonist O
. O

It O
acts O
on O
endogenous O
mu-opioid O
receptors O
that O
are O
spread O
in O
discrete O
packets O
throughout O
the O
brain O
, O
spinal O
cord O
and O
gut O
in O
almost O
all O
mammals O
. O

Heroin O
, O
along O
with O
other O
opioids B-PHE
, O
are O
agonists O
to O
four O
endogenous B-PHE
neurotransmitters I-PHE
. O

They O
are O
beta-endorphin B-PHE
, O
dynorphin B-PHE
, O
leu-enkephalin B-PHE
, O
and O
met-enkephalin B-PHE
. O

The O
body O
responds O
to O
heroin O
in O
the O
brain O
by O
reducing O
( O
and O
sometimes O
stopping O
) O
production B-PHE
of I-PHE
the I-PHE
endogenous I-PHE
opioids I-PHE
when O
heroin O
is O
present O
. O

Endorphins B-PHE
are O
regularly O
released O
in O
the O
brain B-PHE
and O
nerves B-PHE
, O
attenuating O
pain B-PHE
. O

Their O
other O
functions O
are O
still O
obscure O
, O
but O
are O
probably O
related O
to O
the O
effects O
produced O
by O
heroin O
besides O
analgesia B-PHE
( O
antitussin O
, O
anti-diarrheal O
) O
. O

-DOCSTART- O


Liver B-PHE
health I-PHE
, O
Liver B-PHE

-DOCSTART- O


the O
ulcerated B-PHE
mouth I-PHE
turns O
to O
the O
aphtha B-PHE

-DOCSTART- O


Stage O
III O
Adult B-PHE
T-Cell I-PHE
Leukemia/Lymphoma I-PHE

-DOCSTART- O


recurrent B-PHE
fever I-PHE
by O
the O
exhaustion B-PHE
after O
healing O
from O
pyogenic B-PHE
febrile I-PHE
disease I-PHE
. O

-DOCSTART- O


Used O
mainly O
in O
female B-PHE
infertility I-PHE
due O
to O
anovulation B-PHE
( O
e.g O
. O
due O
to O
polycystic B-PHE
ovary I-PHE
syndrome I-PHE
) O
to O
induce O
ovulation B-PHE
. O

-DOCSTART- O


lingual B-PHE
pustule I-PHE
; O
boil B-PHE
of O
the O
tongue O

-DOCSTART- O


harmonize O
blood B-PHE

-DOCSTART- O


refers O
to O
the O
heavy B-PHE
coughing I-PHE
and O
shortness B-PHE
of I-PHE
breath I-PHE
due O
to O
the O
heat B-PHE
In I-PHE
the I-PHE
lung I-PHE

-DOCSTART- O


destroy O
intestinal B-PHE
parasites I-PHE

-DOCSTART- O


dissipate O
blood B-PHE

-DOCSTART- O


Breast B-PHE
Pain I-PHE

-DOCSTART- O


Abscess B-PHE

-DOCSTART- O


Gastric B-PHE
Varices I-PHE

-DOCSTART- O


Carpal B-PHE
Tunnel I-PHE
Syndrome I-PHE

-DOCSTART- O


malignant B-PHE
furuncle I-PHE
due O
to O
scrofula B-PHE
. O

-DOCSTART- O


relieve O
fever B-PHE

-DOCSTART- O


hemoptysis B-PHE
; O
coughing B-PHE
up I-PHE
blood I-PHE

-DOCSTART- O


Treament O
of O
arthritis B-PHE
with O
ankylosis B-PHE
, O
aching B-PHE
and I-PHE
heaviness I-PHE
sensation I-PHE
of O
the O
loins O
and O
knees O
, O
systremma B-PHE
due O
to O
vomiting B-PHE
and O
diarrhea B-PHE
, O
edema B-PHE
and O
weakness B-PHE
of I-PHE
the I-PHE
legs I-PHE
. O

-DOCSTART- O


absorption B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
motility O

-DOCSTART- O


To O
eliminate O
blood B-PHE
stasis I-PHE
, O
arrest O
bleeding B-PHE
, O
cause O
subsidence O
of O
swelling B-PHE
and O
alleviate O
pain B-PHE
. O

-DOCSTART- O


clear O
the O
heart B-PHE
and O
relieve O
vexation B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Physical B-PHE
performance B-PHE
and O
fitness B-PHE
, O
absorption B-PHE
, O
Lipid O
profile O
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Strength B-PHE
and O
power B-PHE
, O
Others O
, O
motility B-PHE

-DOCSTART- O


S B-PHE
. I-PHE
Aureus I-PHE
Bacteremia I-PHE

-DOCSTART- O


damp-warm B-PHE
disease I-PHE
febrile B-PHE
disease I-PHE
often O
occurring O
around O
mid-summer O
, O
July O
, O
caused O
by O
damp-heat B-PHE
pathogene I-PHE
, O
which O
mainly O
involves O
the O
gastro-intestinal B-PHE
tract I-PHE
often O
in O
a O
protracted O
course O
. O

It O
may O
sometimes O
be O
seen O
in O
diseases O
such O
as O
typhoid B-PHE
fever I-PHE
. O

-DOCSTART- O


Exciting O
the O
intestinal B-PHE
smooth I-PHE
muscles I-PHE
in O
vivo O
or O
in O
vitro O
, O
and O
relaxing O
the O
uterus B-PHE
of O
guinea-pigs O
in O
vitro O
. O

-DOCSTART- O


To O
supplement O
kidney B-PHE
and O
boost O
essence O
, O
warm O
lung B-PHE
and O
settle O
asthma B-PHE
, O
moisten O
intestines B-PHE
and O
free O
stool B-PHE
. O

-DOCSTART- O


To O
promote O
blood B-PHE
circulation I-PHE
to O
remove O
blood B-PHE
stasis I-PHE
, O
soothe O
the O
liver B-PHE
and O
remove O
the O
obstruction B-PHE
in O
the O
channels O
. O

-DOCSTART- O


Protective B-PHE
immunity I-PHE
, O
Others O
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Others O
health B-PHE
and O
immunity B-PHE
, O
Metabolism B-PHE

-DOCSTART- O


Hepatitis B-PHE
B I-PHE
Virus I-PHE

-DOCSTART- O


1 O
nocturnal O
enuresis O
; O
bed-wetting O
2 O
incontinence O
of O
urine O

-DOCSTART- O


Deficiency B-PHE
of O
both O
qi O
and O
blood B-PHE
marked O
by O
pallor B-PHE
, O
shortness B-PHE
of I-PHE
breath I-PHE
, O
cardiac B-PHE
palpitation I-PHE
, O
dizziness B-PHE
, O
spontaneous B-PHE
sweating I-PHE
, O
lassitude B-PHE
and O
cold B-PHE
extremities I-PHE
, O
or O
excessive O
menstrual B-PHE
discharge I-PHE
. O

-DOCSTART- O


Solid B-PHE
Tumors I-PHE

-DOCSTART- O


asthma B-PHE
and O
cough B-PHE

-DOCSTART- O


This O
means O
urolithiasis B-PHE
made O
of O
coagulation B-PHE
of I-PHE
phlegm I-PHE
. O

-DOCSTART- O


Erlotinib O
inhibits O
the O
intracellular B-PHE
phosphorylation I-PHE
of I-PHE
tyrosine I-PHE
kinase I-PHE
associated O
with O
the O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
which O
is O
expressed O
on O
the O
cell O
surface O
of O
normal O
cells B-PHE
and O
cancer B-PHE
cells I-PHE
. O

-DOCSTART- O


metrorrhagia B-PHE

-DOCSTART- O


1 O
Applicable O
to O
edema B-PHE
of I-PHE
wind I-PHE
type O
attributive O
to O
attack O
of O
dampness B-PHE
and O
heat B-PHE
, O
which O
is O
manifested O
as O
general O
edema B-PHE
beginning O
from O
the O
eyelids O
, O
dyuria B-PHE
, O
fever B-PHE
, O
chilliness B-PHE
, O
white B-PHE
and I-PHE
greasy I-PHE
fur I-PHE
on O
the O
tongue O
and O
slow B-PHE
pulse I-PHE
. O
2 O
Also O
applicable O
to O
urinar B-PHE

-DOCSTART- O


headache B-PHE
due O
to O
cold B-PHE
affection O

-DOCSTART- O


This O
is O
damp-arthritis B-PHE
caused O
by O
apoplectoid B-PHE
syndrome I-PHE
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
absorption B-PHE
, O
Lipid O
profile O
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
motility B-PHE
, O
Evacuation B-PHE

-DOCSTART- O


tinea B-PHE
favosa I-PHE
; O
mouth-corner B-PHE
ulcer I-PHE

-DOCSTART- O


Chlorambucil O
alkylates O
and O
cross-links O
DNA O
during O
all O
phases O
of O
the O
cell O
cycle O
, O
resulting O
in O
disruption B-PHE
of I-PHE
DNA I-PHE
function I-PHE
, O
cell B-PHE
cycle I-PHE
arrest I-PHE
, O
and O
apoptosis O
. O

-DOCSTART- O


infantile B-PHE
convulsion I-PHE
; O
child O
fright O
epilepsy B-PHE

-DOCSTART- O


sore B-PHE
throat I-PHE
; O
swollen B-PHE
and I-PHE
pailful I-PHE
throat I-PHE

-DOCSTART- O


replenish O
Gi O
( O
Qi O
) O
and O
invigorate O
the O
spleen B-PHE

-DOCSTART- O


brighten O
the O
eyes B-PHE

-DOCSTART- O


A O
symptom O
that O
Gi O
gets O
together O
and O
blood B-PHE
does O
not O
circulate O
well O
. O

An O
affected O
part O
has O
abdominal B-PHE
distension I-PHE
or O
a O
sore B-PHE
. O

If O
it O
keeps O
long O
, O
it O
becomes O
blood B-PHE
stagnation I-PHE
, O
and O
causes O
a O
hard B-PHE
swelling I-PHE
and O
a O
serious B-PHE
pain I-PHE
on O
the O
part O
. O

-DOCSTART- O


all O
kinds O
of O
disease O
due O
to O
wind B-PHE

-DOCSTART- O


Treatment O
of O
deficient O
yin O
of O
the O
liver O
and O
kidneys O
and O
hyperactivity O
of O
liver O
yang O
manifested O
as O
distension B-PHE
and I-PHE
pain B-PHE
in I-PHE
the I-PHE
head I-PHE
and I-PHE
eyes I-PHE
, O
dizziness B-PHE
and O
vertigo B-PHE
. O

Red O
ochre O
( O
Daizheshi O
) O
is O
used O
with O
Dragon's O
bone O
( O
Longgu O
) O
, O
Oyster O
shell O
( O
Muli O
) O
, O
White O
peony O
root O
( O
Bais O

-DOCSTART- O


Promoting O
bile B-PHE
secretion I-PHE
. O

-DOCSTART- O


SR O
58611 O
has O
positive B-PHE
chronotropic I-PHE
effect I-PHE
which O
is O
mainly O
of O
peripheral O
origin O
and O
can O
be O
attributed O
to O
a O
baroreceptor-mediated B-PHE
reflex I-PHE
due O
to O
the O
beta3-adrenoceptor B-PHE
mediated I-PHE
vasodilation I-PHE
with O
an O
increase O
in O
sympathetic B-PHE
tone I-PHE
and O
a O
reduction B-PHE
in I-PHE
vagal I-PHE
tone I-PHE
to I-PHE
the O
heart O
. O

-DOCSTART- O


Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Blood B-PHE
pressure I-PHE

-DOCSTART- O


abdominal B-PHE
distension I-PHE
; O
distension B-PHE
of I-PHE
abdomen I-PHE
with O
a O
gas O
or O
fluid O

-DOCSTART- O


shortness B-PHE
of I-PHE
breath I-PHE
short O
, O
rapid B-PHE
and I-PHE
interrupted I-PHE
breathing I-PHE
, O
and O
anguish B-PHE
with O
chest B-PHE
congestion I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
chronic B-PHE
gouty I-PHE
arthritis I-PHE
when O
complicated O
by O
frequent O
, O
recurrent O
acute O
attacks O
of O
gout B-PHE
. O

-DOCSTART- O


For O
malaria B-PHE
, O
applying O
crushed O
product O
on O
Neiguan O
( O
P.6 O
) O
and O
Dazhui O
( O
Du' O
14 O
) O
2 O
hours O
before O
the O
episode O
; O
alos O
used O
for O
dyspnea B-PHE
due O
to O
the O
retention B-PHE
of I-PHE
phlegm I-PHE
. O

-DOCSTART- O


Woman O
, O
Mood O
, O
Menopausal B-PHE
woman I-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
General O
woman O
, O
General O
skin B-PHE
health I-PHE
, O
Others O
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


calm O
the O
fetus O

-DOCSTART- O


To O
relieve O
dyspnea B-PHE
and O
cough B-PHE
by O
eliminating O
cold-phlegm B-PHE
, O
to O
reduce O
modulation O
, O
and O
to O
relieve O
pain B-PHE
by O
removing O
the O
obstruction O
of O
collateral O
. O

-DOCSTART- O


To O
dispel O
cold B-PHE
, O
eliminate O
damp B-PHE
and O
phlegm B-PHE
, O
and O
to O
arrest O
emesis B-PHE
or O
nausea B-PHE
. O

-DOCSTART- O


epilepsy B-PHE
induced O
by O
frightening B-PHE
and O
mania-withdrawal B-PHE

-DOCSTART- O


join O
cutting B-PHE
wound I-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
relieve O
pain B-PHE
, O
soothe O
sinews B-PHE
and O
quicken O
network O
vessels B-PHE
. O

-DOCSTART- O


Treatment O
of O
epistaxis B-PHE
, O
spitting B-PHE
of I-PHE
blood I-PHE
, O
hematuria B-PHE
, O
hematochezia B-PHE
, O
abnormal B-PHE
uterine I-PHE
bleeding I-PHE
, O
traumatic B-PHE
bleeding I-PHE
, O
carbuncles B-PHE
and O
sores B-PHE
. O

-DOCSTART- O


To O
remove O
heat O
from O
the O
lung B-PHE
, O
and O
to O
relieve O
cough B-PHE
and O
dyspnea B-PHE
. O

-DOCSTART- O


exhaustion B-PHE
syndrome I-PHE
; O

consumption B-PHE
; O

exhaustion B-PHE
of I-PHE
strength I-PHE
; O

overstrain B-PHE
; O

asthenic B-PHE
disease I-PHE
; O

weakness B-PHE
and O
fatigue B-PHE

-DOCSTART- O


free O
the O
kidney B-PHE
and O
water O

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Inflammation B-PHE
, O
Others O

-DOCSTART- O


postpartum B-PHE
anemic I-PHE
faintness I-PHE
; O
faint B-PHE
after O
childbirth O

-DOCSTART- O


cosolidate O
the O
kidney B-PHE

-DOCSTART- O


eczema B-PHE

-DOCSTART- O


Kidney B-PHE
Cancer I-PHE

-DOCSTART- O


Dimethindene O
is O
also O
indicated O
for O
pruritus B-PHE
in O
eruptive B-PHE
skin I-PHE
diseases I-PHE
such O
as O
chicken-pox B-PHE
. O

-DOCSTART- O


The O
hormones O
, O
T O
4 O
and O
T O
3, O
are O
tyrosine-based O
hormones O
produced O
by O
the O
thyroid O
gland O
. O

Iodine O
is O
an O
important O
component O
in O
their O
synthesis O
. O

The O
major O
secreted O
form O
of O
thyroid O
hormone O
is O
T4 O
. O

T4 O
is O
converted O
T3 O
, O
the O
more O
active O
thyroid O
hormone O
, O
by O
deiodinases O
in O
peripheral O
tissues O
. O

T3 O
acts O
in O
the O
body O
to O
increase O
basal B-PHE
metabolic I-PHE
rate I-PHE
, O
alter O
protein B-PHE
synthesis I-PHE
and O
increase O
the O
body's B-PHE
sensitivity I-PHE
to O
catecholamines O
( O
such O
as O
adrenaline O
) O
. O

Thyroid O
hormones O
are O
essential O
for O
proper O
development O
and O
differentiation O
of O
all O
cells O
of O
the O
human O
body O
. O

T O
4 O
and O
T O
3 O
regulate O
protein O
, O
fat O
and O
carbohydrate O
metabolism O
to O
varying O
extents O
. O

The O
most O
pronounced O
effect O
of O
the O
hormones O
is O
in O
altering O
how O
human O
cells O
use O
energetic O
compounds O
. O

The O
thyroid O
hormone O
derivatives O
bind O
to O
the O
thyroid O
hormone O
receptors O
initially O
to O
initiate O
their O
downstream B-PHE
effects I-PHE
. O

-DOCSTART- O


N(omega)-Nitro-L-arginine O
methyl O
ester O
( O
L-NAME O
) O
induces O
a O
pre-eclampsia-like B-PHE
syndrome I-PHE
in O
pregnant O
rats O
. O

We O
have O
previously O
reported O
the O
anti-hypertensive B-PHE
effects I-PHE
of O
several O
Japanese O
traditional O
( O
Kampo O
) O
medicines O
in O
this O
model O
, O
and O
one O
of O
these O
, O
Tokishakuyakusan O
( O
TS O
) O
, O
also O
improved O
intrauterine B-PHE
growth I-PHE
retardation I-PHE
( O
IUGR O
) O
. O

In O
the O
present O
study O
, O
we O
characterized O
the O
effect O
of O
TS O
on O
IUGR O
. O

TS O
administration O
reversed O
the O
decrease O
in O
fetal O
body B-PHE
weight I-PHE
and O
fetal O
blood B-PHE
glucose I-PHE
concentration I-PHE
induced O
by O
the O
infusion O
of O
L-NAME O
. O

Growth O
hormone O
( O
GH O
) O
levels O
in O
the O
fetal O
blood B-PHE
, O
which O
were O
decreased O
by O
L-NAME O
infusion O
, O
were O
also O
significantly O
elevated O
by O
TS O
; O

however O
, O
levels O
of O
GH O
releasing O
hormone O
( O
GHRH O
) O
and O
insulin-like O
growth O
factor O
I O
( O
IGF-I O
) O
were O
unchanged O
and O
only O
slightly O
changed O
, O
respectively O
. O

Treatment O
with O
L-NAME O
with O
or O
without O
TS O
had O
no O
apparent O
effect O
on O
GH O
, O
GHRH O
, O
and O
IGF-I O
levels O
of O
dams O
. O

In O
an O
immunocytochemical O
study O
, O
the O
number O
of O
GH-positive O
cells O
in O
the O
fetal O
pituitary O
gland O
was O
significantly O
increased O
in O
TS-treated O
rats O
. O

These O
data O
suggest O
that O
enhanced O
proliferation O
of O
somatotrope O
cells O
of O
the O
pituitary O
gland O
and O
the O
resultant O
increase O
in O
GH O
secretion O
in O
the O
fetus O
may O
be O
involved O
in O
the O
improvement O
of O
IUGR O
by O
TS O
. O

-DOCSTART- O


External O
use O
for O
vitiligo B-PHE
and O
alpecia B-PHE
areata I-PHE
. O

-DOCSTART- O


To O
replenish O
the O
liver B-PHE
and O
the O
kidney B-PHE
, O
and O
to O
arrest O
bleeding B-PHE
by O
removing O
heat B-PHE
from I-PHE
blood I-PHE
. O

-DOCSTART- O


Infertility B-PHE

-DOCSTART- O


Hyperuricemia B-PHE

-DOCSTART- O


Traumatic B-PHE
injury I-PHE
with O
ecchymosis B-PHE
, O
swelling B-PHE
and O
pain B-PHE
. O

-DOCSTART- O


thirst B-PHE
with O
fever B-PHE

-DOCSTART- O


invigorate O
the O
spleen B-PHE
and O
disperse O
food O

-DOCSTART- O


deficiency B-PHE
syndrome I-PHE
after O
delivery O

-DOCSTART- O


Prednisone O
enters O
the O
nucleus O
where O
it O
binds O
to O
and O
activates O
specific O
nuclear O
receptors O
, O
resulting O
in O
an O
altered O
gene B-PHE
expression I-PHE
and O
inhibition O
of O
proinflammatory B-PHE
cytokine I-PHE
production I-PHE
. O

-DOCSTART- O


To O
replenish O
blood B-PHE
, O
activate O
circulation B-PHE
and O
regulate O
menstruation B-PHE
. O

-DOCSTART- O


pain B-PHE
and I-PHE
swelling I-PHE
of I-PHE
testis I-PHE

-DOCSTART- O


Nephrolithiasis B-PHE

-DOCSTART- O


Treatment O
of O
consumptive B-PHE
diseases I-PHE
, O
impotence B-PHE
, O
cold B-PHE
sperm I-PHE
, O
lassitude B-PHE
in O
the O
loins O
and O
legs O
due O
to O
deficiency O
of O
the O
kidney-yang O
, O
etc O
. O

-DOCSTART- O


Used O
in O
the O
treatment O
of O
rheumatoid B-PHE
arthritis I-PHE
. O

-DOCSTART- O


breast B-PHE
abscess I-PHE
; O
abscess B-PHE
of I-PHE
breast I-PHE
; O
acute B-PHE
mastitis I-PHE

-DOCSTART- O


three O
Eum O
syndrome O
of O
cold O
attack O

-DOCSTART- O


1 O
Its O
decoction O
acts O
as O
an O
antitussive O
and O
expectorant O
in O
mice O
. O

2 O
Inhibiting O
the O
growth B-PHE
of I-PHE
pneumococcus B-PHE
and O
beta-streptococcus B-PHE
in O
vitro O
. O

-DOCSTART- O


sore B-PHE
; O
pain B-PHE
; O
to O
ache B-PHE

-DOCSTART- O


